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ABSTRACT

EXTERNAL VALIDATION AND COST EFFECTIVENESS ANALYSIS OF THE
NON-LB FRAMINGHAM CARDIOVASCULAR DISEASE RISK ASSESSMENT
ALGORITHM IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES
DATASET
May 2016

Jacob K. Kariuki, BSN., University of Eastern Africa Baraton
MS., University of Massachusetts Boston
PhD., University of Massachusetts Boston

Directed by Professor Eileen Stuart-Shor

Background: In recent years, non-Laboratory based (non-LB) risk assessment
algorithms have been developed to facilitate absolute cardiovascular disease (CVD) risk
assessment in resource constrained primary care settings. The non-LB Framingham
algorithm, which substitutes body mass index (BMI) for lipids, has the best
discrimination and calibration among the published algorithms, but its external validity
and cost-effectiveness have not been determined.
Purpose: External validation and comparative effectiveness analysis of the nonLB versus laboratory based (LB) Framingham algorithm in a racially diverse population,
and simulated cost-effectiveness analysis focusing on a black sample.
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Methods: Secondary data analysis was performed using the Atherosclerosis Risk
in Communities (ARIC) dataset. Cox regression models including the non-LB and LB
Framingham covariates were developed. Model discrimination was assessed using the C
statistic, calibration using the goodness-of-fit test, and equivalence of regression
coefficients using the z-test. Algorithms based on the models were developed and their
performance assessed using the area under receiver operating characteristic curve
(AUROC), and agreement using kappa statistics. Analyses using simulated incremental
cost-effectiveness ratios (ICER) were focused on the black sample. IRB approval was
obtained. Data were analyzed using Stata© software version 14.
Results: Among 11,601 individuals (mean age 53.9 ± 5.7 years, 55% female, 24%
black), the non-LB versus LB models performed as follows: C statistic (0.75 vs 0.76 for
women, & 0.67 vs 0.68 for men); goodness-of-fit (14.2 vs 10.5 for women, & 25.8 vs
21.8 for men) respectively. In the black sample, regression coefficients of all covariates
were similar to those generated in Framingham (z = ±1.96). The two algorithms based on
the models had a kappa statistic of 0.76. When used to stratify risk in the entire ARIC
sample, the non-LB and LB Framingham algorithms had AUROC of 0.706 vs 0.710
respectively. Prevention program guided by the non-LB Framingham dominated those
guided by individual risk factors and LB Framingham algorithm.
Conclusions: These results demonstrate the validity and cost-effectiveness of the
non-LB Framingham algorithm. This approach could provide a valuable and efficient
alternative to the traditional LB approaches in the ongoing efforts to address the high
burden of CVD in underserved communities especially the US black population.
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CHAPTER 1
INTRODUCTION
Cardiovascular disease (CVD), including coronary heart disease and stroke, is
now the leading cause of death globally due in part to the ongoing epidemiological
transition from infectious to non-communicable diseases in developing countries (WHO,
2015). Currently over 75% of all CVD deaths occur in developing countries where CVD
is taking toll on populations in resource constrained settings who rely on under-developed
health care systems that are traditionally invested in treating infectious diseases (Mensah,
2008; WHO, 2015). Consequently, most of the CVD mortality and morbidity occur at
younger ages in these countries (S. Mendis et al., 2007; WHO, 2015).
In developed countries such as the United States (US), underserved racial and
ethnic minorities bear the highest burden of CVD (Mozaffarian et al., 2015). The US
black population continues to be disproportionately affected by CVD related morbidity
and mortality. For instance, the age-adjusted mortality attributable to CVD is
approximately 34% higher in the black population compared to the overall US population
(Mozaffarian et al., 2015). Although factors leading to these disparities are complex,
barriers related to access of preventive and curative treatments are known to play a
prominent role (Institute of Medicine, 2001).
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The public health and socioeconomic ramifications of CVD, especially on the
poor and underserved populations in both developed and developing countries require
pragmatic and robust preventive initiatives. Feasible strategies that improve access and
quality of CVD preventive treatments are necessary to address the burden of CVD in
resource constrained settings. If well implemented, such strategies may promote
cardiovascular health and economic progress of minority groups in developed countries,
as well as the economically deprived populations in developing countries.
Contemporary CVD management guidelines recommend absolute risk assessment
as a clinically sound guide to CVD prevention and risk surveillance (Cooney, Dudina, &
Graham, 2009; World Health Organization, 2007). Absolute CVD risk, also known as
total or global risk, denotes the probability that an individual will develop CVD within a
given time frame, depending on the combination and severity of the risk factors present
(Jilcott et al., 2007). To facilitate absolute CVD risk assessment, dozens of algorithms
have been developed to predict the likelihood that a particular constellation of risk factors
will contribute to occurrence of CVD related morbidity or mortality over a specific
period of time (Hayman, Helden, Chyun, & Braun, 2011; D. M. Lloyd-Jones, 2010a).
For many years the available absolute CVD risk assessment algorithms were
based on laboratory measures which are not readily available in resource constrained
settings or for individuals with limited access to care (Beswick, Brindle, Fahey, &
Ebrahim, 2008; Gaziano, Young, Fitzmaurice, Atwood, & Gaziano, 2008). However, in
recent years progress has been made in developing non-LB algorithms, a move that may
be helpful for management of CVD in resource constrained settings.
2

A recent systematic review of literature reported that of the five published non-LB
risk assessment algorithms for primary prevention of CVD, the non-LB Framingham
algorithm had the best sensitivity and specificity ratios (Kariuki, Stuart-Shor, Leveille, &
Hayman, 2013). In the high risk category (ten-year risk threshold of 20%) the algorithm
had sensitivity/specificity ratios of 0.48/0.85 and 0.58/0.83 for men and women
respectfully. These sensitivity/specificity ratios were comparable to the established LB
Framingham algorithm (0.49/0.85 and 0.60/0.84) for men and women respectfully
(D'Agostino RB et al., 2008).
Despite the solid performance of the non-LB Framingham algorithm in its
predominantly white (99.7%) derivation dataset, its performance and applicability in
multiracial and black populations has not been tested. External validation is considered to
be an essential process of testing the applicability of an algorithm to diverse populations
with baseline characteristics which differ from those in the algorithm’s derivation dataset
(Cooney et al., 2009). Without external validation, the suitability of the algorithm beyond
the Framingham population remains uncertain.
This study performed external validation of the non-LB Framingham algorithm in
the multiracial Atherosclerotic Risk in Communities (ARIC) dataset (23% black). The
external validation focused on evaluation of the algorithm’s ability to optimally stratify
CVD risk and predict cardiovascular events in the multiracial population that forms the
ARIC dataset. A sub-analysis focusing on the black participants enlisted in the ARIC
study assessed the performance of the algorithm in a group that bears the highest burden
of CVD, and more likely to reside in resource constrained or underserved settings in the
3

US. A subsequent cost effectiveness analysis evaluated the costs and benefits associated
with using the algorithm in guiding prevention of CVD in the black participants enlisted
in the ARIC study. Race was self-reported and individuals who report black race or white
race will hereafter be referred to as “blacks” and “whites” respectively.
Goals of the Study
The main purpose of this study was to externally validate and cost the non-LB
Framingham algorithm by testing four hypotheses to achieve three aims: Specific aim 1: Assess the accuracy of the non-LB Framingham algorithm in
stratifying risk and predicting CVD events a racially diverse population.
Hypothesis 1: Non-LB Framingham algorithm will have adequate discrimination
(Harrell’s C statistic greater than 0.75) and calibration (Hosmer-Lemeshow goodness of
fit (χ 2) below 20 (p>0.05) in the multiracial ARIC dataset.
Specific aim 2: Compare the performance of the non-LB Framingham algorithm
in black versus white participants of the ARIC study.
Hypothesis 2: There will be no significant difference in discrimination and
calibration of the non-LB Framingham algorithm between the black and white
participants of the ARIC study.
Specific aim 3: Establish the cost feasibility of using the non-LB Framingham
algorithm in guiding prevention of CVD among the black participants enlisted the ARIC
study.
Hypothesis 3: A CVD prevention strategy guided by the non-LB Framingham
algorithm will be more cost-effective compared with treating each elevated CVD risk
4

factor (diabetes and/or hypertension) independently in the black subset of the ARIC
cohort.
Hypothesis 4: A CVD prevention strategy guided by the non-LB Framingham
algorithm will be more cost-effective compared to a strategy guided by the LB
Framingham algorithm in the black subset of the ARIC cohort.
Significance and Innovation
Validating and costing the non-LB Framingham algorithm was an important step
in availing a risk assessment tool that could guide CVD prevention in resource
constrained settings. The high representation of blacks in the ARIC cohort (23%) enabled
adequate evaluation of the algorithm’s performance in this population that has the highest
rates of CVD in the US.
Defining Key terms
In this study, the performance of the non-LB Framingham algorithm is assessed
through external validation. External validation is the assessment of the performance of
an algorithm in an external dataset. The external validation process is considered an
essential step in assessing transportability of an algorithm to different populations
because baseline survival and risk factors used in the test are not a perfect match for those
in the algorithm’s derivation dataset (Cooney et al., 2009).The main approaches for
measuring the performance include discrimination, and calibration.
Discrimination is the ability of an algorithm to assign a higher risk to those who will
develop the end point and a lower score to those who will not, and it is frequently
measured using area under Receiver Operating Characteristic curve (AUROC) or
5

Harrell’s C statistic. AUROC or C statistic of 1 denotes perfect discrimination whereas
0.5 equates to chance discrimination. Although the C statistic of CV risk assessment
algorithms rarely exceeds 0.8, a valid algorithm should have a C statistic of 0.75 or
higher (Cooney et al., 2009; May, Lawlor, Brindle, Patel, & Ebrahim, 2006). In addition,
threshold discrimination operationalized by sensitivity and specificity is used to define
low/high risk populations and treatment decisions are made in reference to this threshold
(Cooney et al., 2009).
Calibration is a measure of the agreement between the predicted outcomes and
observed outcomes. It is frequently assessed using Hosmer-Lemeshow goodness of fit
testing (χ 2). Goodness of fit (χ 2) values below 20 (lack of fit, p>0.05) are considered
good fit (Cooney et al., 2009).
Conceptual Framework
The proposed study was guided by the Social Ecological and Chronic Care
Models which are combined and adapted to provide an organizing structure for testing
the validity and cost-effectiveness of the non-LB Framingham algorithm (see Figure 1).
Various socioecological models were developed after the First World War to
expand understanding of the dynamic relationship between various personal and
environmental factors. In 1991 Dahlgren and whitehead published the Social Ecological
Model to enhance understanding of policies and strategies to promote social equity in
health. They contended that policies and strategies focusing on health equity should be
based on a clear understanding of factors that threaten, promote or protect health
(Dahlgren & Whitehead, 1991).
6

In the Social Ecological framework, the major factors that influence health are
organized in hierarchical layers which include: macro-socioeconomic environment, living
and work conditions, social and community networks, lifestyle choices, and
genetical/constitutional factors (Dahlgren & Whitehead, 1991). The postulated influence
of these interactive layers resonates with current knowledge on cardiovascular health
trajectory which is known to be influenced by the interrelation between personal and
environmental factors over an individual's lifetime (Hayman et al., 2011; Stuart-Shor,
Berra, Kamau, & Kumanyika, 2012).
Personal factors, which include genetics and lifestyle, form the core of the model
are affected by, and affect the social determinants of health which are espoused in the
three outer layers of the Social Ecological model (see Figure 1). The social determinants
of health include life improving resources such as food supply, education, and social
relationships, and their distribution across populations is well known to impact the health
trajectory (Will, Keydron, Cynthia, Luis, & Zachary, 2011).
The Chronic Care Model was developed by Dr. Edward Wagner and colleagues
as part of the “Improving Chronic Illness Care initiative” supported by the Robert Wood
Johnson Foundation (Bodenheimer, Wagner, & Grumbach, 2002). The initiative sought
to develop innovations in primary care that would help close the quality gaps described in
the 2001 Institute of Medicine report titled: Crossing the Quality Chasm: A New Health
System for the 21st Century. In the report, the Institute of Medicine detailed many quality
problems that caused a huge gap between current practices and attainable optimal chronic
illness care in the US (Institute of Medicine, 2001).
7

To address these problems, the Chronic Care Model identifies the entire
community, health care systems, and provider organizations as the three galaxies where
chronic illness care occur (Bodenheimer et al., 2002). The three galaxies overlap and
encompass six essential elements or pillars which may undermine or promote chronic
illness care. The six pillars include: community resources and policies, self-management
support, health care organization, delivery system design, decision support, and clinical
information systems (Barr et al., 2003; Bodenheimer et al., 2002). Improvements in these
six essential and interrelated pillars are expected to produce reformed health care systems
in which informed, activated patients interact with prepared, proactive health care
providers (Bodenheimer et al., 2002).
Although the six pillars of the Chronic Care Model are interrelated, only the
decision support pillar is directly relevant to the objectives of this study as outlined in
Figure 1. Therefore, the discussion of the other five pillars is beyond the scope of this
study. The decision support pillar calls for integration of evidence based guidelines in
routine protocols to help clinicians in making prudent clinical decisions in management
chronic illness (Bodenheimer et al., 2002).
Decision support is not intended to substitute individualized clinical judgement,
but to support it by providing real time essential data on the patient or available evidence
based interventions to the clinician. Optimal decision support tools may also promote
self-management by making complex concepts more concrete and comprehensible to the
patient; hence increasing risk awareness and motivation to adhere to risk reduction
interventions.
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The value of any tool used to support clinical decisions depends on the extent to
which it is valid and applicable to the relevant clinical practice. Generally clinicians are
more likely to use decision support tools that are not only valid, but also quick and easy
to use (Cooney et al., 2009; Gaziano et al., 2008). The need for valid but simple, user
friendly decision support tools is even more acute in resource constrained settings where
non-physician health workers are increasingly being entrusted with traditionally
physician responsibilities such as screening for and managing CVD.
Absolute CVD risk assessment algorithms are considered as valid decision
support tools appropriate for guiding CVD risk assessment and management.
Consequently, the algorithms are currently used in many developed countries to support
clinical decisions on CVD management by providing guidance on risk stratification and
selection of treatment intensity (D. M. Lloyd-Jones, 2010b). In resource constrained
settings, these algorithms are rarely used because they require laboratory measures that
are usually inaccessible in these settings. Therefore, validating and costing the non-LB
Framingham algorithm was an important step in availing a tool that would support
implementation of evidence based guidelines in routine management of CVD.
The absolute risk assessment algorithms use some covariates which are influenced
by the dynamic relationship between personal and environmental factors included in the
Social Ecological Model. Equipping healthcare providers with a decision support tool
that enables them to have a comprehensive view of factors that threaten, promote or
protect cardiovascular health is expected to make them well prepared and proactive in
prevention and management of CVD. Individuals and populations served by such
9

proactive providers will have improved access to timely CVD risk assessment, increased
risk awareness, and motivation to adherence.
The Conceptual Theoretical and Empirical (CTE) structure
The Social Ecological model’s proposition that a dynamic relationship between
personal factors and the social determinants of health dictates the individual’s level of
risk and subsequent development of disease forms the central concept of the framework.
The chronic care model’s conceptualization of the importance of clinical decision support
in shaping the dynamic relationship between personal factors and social determinants of
health in favor of optimal cardiovascular health forms the middle range theory of the
framework. Empirical indicators will include discrimination and calibration statistics
quantifying the contribution of clinical decision support tool (non-LB Framingham CVD
risk assessment algorithm) in detecting individual’s level of risk. Quantification of risk is
expected to foster risk reduction discussion thereby producing proactive and well
prepared healthcare providers and activate patients.

10

Figure 1: The Social Ecological & Chronic Care Model adapted to focus on CVD
Macrosocioeconomic
Environment
Living &
Working
Conditions
Social &
Community
Networks

Personal
Factors

Clinical decision support:
Non-LB Framingham
algorithm

Optimal CVD risk
discrimination &
calibration

In chapter 1, the concept of absolute CVD risk assessment and the role of valid
and feasible risk assessment algorithms were introduced. The external validation process
as well as the organizing framework for the study were also presented in the context of
CVD. Chapter 2 will focus on the science behind these concepts and existing knowledge
gaps pertaining to CVD risk assessment in resource constrained settings.
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CHAPTER 2
LITERATURE REVIEW
Background
Although the morbidity and mortality associated with CVD usually occur in
middle and late adulthood, the main pathological pathway leading to CVD begins early in
life and progresses cumulatively through adolescence and early adulthood (World Health
Organization, 2007). This lifelong cumulative process is influenced by the interaction
between constitutional (genetic) and lifestyle factors, with social determinants of health
such as education and socioeconomic status as exemplified in the widely published social
ecological model (Golden & Earp, 2012; Whitehead & Dahlgren, 1991).
The insidious progression of CVD risk necessitates timely detection and initiation of
preventive treatments. The major risk factors known to independently increase the risk of
CVD include: cigarette smoking, high blood pressure, dyslipidemia, diabetes mellitus,
and advancing age (Grundy, Pasternak, Greenland, Smith, & Fuster, 1999). Predisposing
risk factors are known to aggravate the major CVD risk factors and include; obesity,
physical inactivity, family history of premature CVD, ethnic characteristics, and
psychosocial factors (Grundy et al., 1999). Co-occurrence or clustering of these risk
factors is known to compound the effect of individual risk factors increasing the
likelihood of developing CVD (World Health Organization, 2007)
12

Absolute CVD risk assessment algorithms are recommended by contemporary
CVD management guidelines to facilitate assessment of “total” or “global” risk. These
algorithms take into consideration the clustering of risk factors in an individual to predict
their likelihood of experiencing a CVD event within a given time frame, usually 10 years
(Beswick et al., 2008). The foremost absolute risk assessment algorithms were derived
from the Framingham Heart Study which was inaugurated in 1948 to investigate risk
factors associated with development of CVD. At the commencement of the study, the
town of Framingham was an industrial trading center in North Eastern United States
inhabited by white middle class families (Dawber, Meadors, & Moore, 1951). As a result,
the cohort was 99.7% white. In 1971, descendants of the original cohort and their spouses
were recruited to form the Framingham offspring cohort with an overarching goal of
mapping the familial and genetic determinants of CVD. Similar protocols have been used
in the examination of the original and offspring cohorts so as to enable combined
analyses (Beswick et al., 2008).
As part of the premier cardiovascular research study, the Framingham cohorts
have been instrumental in identifying many CVD risk factors. The identified risk factors
have been progressively included in the Framingham based algorithms, enabling
significant improvements in risk discrimination and calibration (Beswick et al., 2008).
High-density lipoprotein (HDL) cholesterol was identified and incorporated into
Framingham risk assessment algorithms as an independent risk factor for CVD in 1968
(Beswick et al., 2008). Traditionally, the Framingham algorithms have required
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laboratory measures and were tailored to estimate the 10-year risk of developing coronary
heart disease (Cooney et al., 2009).
In an effort to simplify absolute CVD risk assessment, D'Agostino RB et al. (2008)
developed a risk prediction model that demonstrated that Body Mass Index (BMI) could
effectively substitute total and HDL cholesterol without compromising the robustness of
the Framingham model. In the same study, the focus of risk assessment was broadened
from a narrow focus on hard coronary events to a broader focus that entailed the full
spectrum of CVD.
The 2008 update of the Framingham model includes the simplified non-LB algorithm
and the LB algorithm. Both the non-LB and LB algorithms were also modelled to predict
general CVD events (coronary heart disease, cerebrovascular events, peripheral artery
disease and heart failure). As a result of this broad focus, the absolute CVD risk
estimated using the updated 2008 algorithms is significantly higher than when using
earlier versions of Framingham model (D'Agostino RB et al., 2008).
The predicted CVD risk (𝑝̃) in both the non-LB and LB algorithms is calculated using
𝑝

̇

𝑝

̇

the general formulae: 𝑝̃ = 1 − S0 (𝑡)exp(∑𝑖 =1 𝛽𝑖𝑋𝑖−∑𝑖 =1 𝛽𝑖𝑋̅𝑖) where S0 (𝑡) is baseline
survival at follow-up time t (here t=12 years), 𝛽̇ 𝑖 is the estimated regression coefficient,
𝑋𝑖 is the log-transformed value of the ith risk factor, (if continuous), 𝑋̅𝑖 is the
corresponding mean, and p denotes the number of risk factors (D'Agostino RB et al.,
2008).
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The 2008 non-LB and LB Framingham algorithms use similar covariates (risk
factors) except for substitution of BMI for cholesterol in the non-LB model as outlined in
Table 1 (D'Agostino RB et al., 2008). This substitution had a benign effect on the model
because both the non-LB and LB algorithms had comparable discrimination (C=0.749 vs.
0.763 men & 0.785 vs. 0.793 women) and equally good calibration (χ 2 =13.61 vs. 13.48
men & 10.24 vs. 7.79 women) in their derivation dataset respectively (D'Agostino RB et
al., 2008). Although the Framingham cohort is more than 99% white, previous studies
have suggested that Framingham risk prediction functions generally perform well in
predicting coronary heart death and myocardial infarction among the US black
population (D'Agostino RB, Grundy, Sullivan, Wilson, & CHD Risk Prediction Group,
2001b).
In 2011, the 2008 LB Framingham model was tested in the multiracial third National
Health and Nutrition Examination Survey (NHANES III) population, where it
demonstrated optimal discrimination (C=0.776 men & 0.834 women); but calibration was
not assessed due to lack of data on clinical end points (Pandya, Weinstein, & Gaziano,
2011). The non-LB Framingham algorithm has been used to assess the effectiveness and
impact of simulated national wide CVD screening strategies in Malaysia, but no
published external validation studies have been found so far (Kariuki et al., 2013;
Selvarajah et al., 2013). Therefore, validating and costing the non-LB algorithm in a
multiracial population is an important step in availing a tool that could be instrumental in
guiding prevention of CVD in resource constrained settings.
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Table 1: Sample characteristics and end points used in Framingham vs ARIC cohorts

Algorithms/Dataset
LB-Framingham
(D'Agostino RB et
al., 2008).

Non-LB
Framingham
(D'Agostino RB et
al., 2008).
ARIC dataset
(ARIC
Investigators,
1989)

Sample
characteristics
Design:
Prospective
study of the
Framingham
Heart Study
and
Framingham
Offspring
cohorts.
Sample: 8491
(0.3% black,
53.3% women)
aged 30-74
yrs., free of
CVD at
baseline exam
(1968-1971)
follow-up:
Biannual
Same as above
(ʺʺ)
Design:
Prospective
study of the
Atherosclerosis
Risk in
Communities
cohort.
Sample:
15,792 (27%
black, 55%
women) aged
45-64 yrs., free
of CVD at
baseline exam
(1987-1989)
follow-up:
Annual

Sex

Age

Smoking

ʺʺ

3074

ʺʺ

M
or
F

ʺʺ
4564

 Yes, selfreported current
smoker
(must be
smoking at the
time of
assessment)
 No, none of
the above
criteria

M
or
F

Yes, selfreported current
smoker (must be
smoking at the
time of
assessment)
 No, none
of the
above
criteria

ʺʺ

 Yes, selfreported
current
treatment
supplemented
by thorough
med review

ʺʺ

Covariates
BP
HTN
Treatment
Systolic
 Yes, selfaverage
reported
of two
current
physician
treatment
obtained
supplemented
measures
by physician
meds review
 No, none of
the above
criteria

Systolic
average
of
2nd & 3rd
measures
obtained
at
baseline
visit

 No, none of
the above
criteria

Cholesterol or
BMI
 Total and
HDL
cholesterol
measured by
standardized
enzymatic
methods

BMI (kg/m²)
measured by
anthropometry
 BMI (kg/m²)
measured by
anthropometry
 Total and
HDL
cholesterol,
and other
biomarkers
measured by
standardized
enzymatic
methods

Diabetes

Endpoints

ʺʺ

General
CVD
(coronary
artery,
cerebrovascular,
and
peripheral
arterial
disease
and heart
failure).

ʺʺ

General
CVD
(coronary
artery and
cerebrovascular
disease,
and heart
failure).

 Yes, fasting
glucose ≥126
mg/dL
(offspring
cohort) or
140 mg/dL
(original
cohort) or use
of insulin/
oral
hypoglycemic
medications.
 No, none of
the above
criteria

 Yes, fasting
glucose ≥126
mg/dL
(variable
DIABTS03)
or 140 mg/dL
(variable
DIABTS02)
or use of
insulin/ oral
hypoglycemic
medications
or history of
DM.
 No, none of
the above
criteria
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The impact of CVD in resource constrained settings
A striking similarity in the epidemiology of CVD in both developed and
developing countries pertains to its impact on underserved populations. Although
developed countries have strong health care systems, advanced medical technologies and
abundance of resources, they are still dominated by high CVD mortality and morbidity
(D. Lloyd-Jones et al., 2010). In 2011 the US spent over three hundred billion dollars to
manage CVD. However, despite the staggering healthcare expenditure, CVD continues to
take a lopsided toll on underserved minority groups especially the black population
(Mozaffarian et al., 2015).
In developing countries which are plagued by infectious diseases and
underdeveloped fragile health care systems, CVD has significantly contributed to a
protracted double burden of disease (S. Mendis et al., 2011). Despite lack of adequate
resources to manage a full blown CVD epidemic, many developing countries are yet to
implement feasible CVD prevention and surveillance initiatives. The inaction continues
to expose masses of vulnerable populations to the dangers of cardiovascular events which
are labor and resource intensive to manage.
The burden and impact of CVD in the black US population
According to the 2015 American Heart Association estimates, about half of all
black adults in the US (48% women, 46% men) are affected by some form of CVD
(Mozaffarian et al., 2015). In addition, US blacks bear a disproportionately high burden
of CVD risk factors including obesity, diabetes, and hypertension. It is estimated that
46% of women and 45% of men in the adult black population have high blood pressure
compared to 33% of the general US population (Mozaffarian et al., 2015). Despite this

17

high burden of CVD, blacks experience delays in CVD diagnosis and usually receive low
quality of care leading to worse health outcomes (Bonow, Grant, & Jacobs, 2005).
Although health disparities are complex and multi-factorial, the high burden of
CVD in US blacks has been related to suboptimal access to the healthcare system,
primary care providers, and preventive health services (Institute of Medicine, 2003). Lack
of insurance coverage and geographic location has been identified as major access
barriers to quality CVD preventive and curative treatments (Escarce, 2007). Overall,
blacks have the second lowest health insurance coverage in every state of the union,
coming only second to the Hispanics (Wilson, 2013). With the escalating cost of health
care, lack of insurance is a major deterrent to optimal health care access.
Geographic location also plays an important role in limiting access to CVD
preventive and curative treatments. Due to low education and high poverty levels, many
US blacks reside in rural areas or inner cities. As a result of high crime rates and/or other
environmental factors, health workers avoid working in inner cities leaving these
populations without adequate health care access. The same trend is observed in most rural
areas which are characterized by resource constrained health care systems and physical
barriers such as distance and unavailability of transportation (Kamble & Boyd, 2008).
These geographic limitations arguably make US blacks more likely to experience
difficulties accessing health care, leading to disparate cardiovascular health outcomes.
The US southern state of Mississippi has been cited as an example of how a
geographical location can be a barrier to health care access. The state has highest
proportion of rural-dwelling black women, and the highest heart disease death rate in the
US (Kamble & Boyd, 2008). Notwithstanding these statistics, over 80% of the counties in
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Mississippi have no physicians who specialize in heart disease (Kamble & Boyd, 2008).
These geographic barriers and other challenges unique to resource constrained settings
necessitates innovativeness to maximize each clinical encounter.
Current policy initiatives aimed at reducing health care access barriers include
subsidies to improve insurance coverage, and incentives to encourage health workers to
provide services in marginalized rural or inner city communities (Brennan, Baker, &
Metzler, 2008; National Rural Health Association, 2013). To reduce the burden of CVD
in the US black population, these policy initiatives need to be supplemented by pragmatic
strategies that would help reduce health care costs without compromising quality.
Validating the non-LB Framingham algorithm in the black sample of ARIC
cohort was an important step in availing a high quality CVD prevention tool that can be
readily used in settings where laboratory measures are inaccessible due to location
constraints or lack of insurance coverage. If validated, the algorithm will allow improved
prediction of CVD events, enabling providers working in marginalized environments to
better identify high risk individuals who require intensive preventive treatments. If used
in combination with counseling, the validated algorithm may help to demonstrate a
patient risk profile and indication for any proposed intervention (Shillinglaw, Viera,
Edwards, Simpson, & Sheridan, 2012). Although absolute CVD risk profile is in the
context of the “average person” calculating the absolute CVD risk score provides a
relatively concrete basis for engaging the patient on the abstract concept of risk. The
ensuing patient-provider risk reduction discussion is likely to foster improved health
literacy and may increase adherence to the prescribed interventions.
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Preventing CVD in resource constrained settings
Integrating absolute CVD risk assessment into routine clinical assessment and
population based surveys may foster a standardized opportunistic and proactive CVD risk
surveillance and prevention in underserved populations. Availability of validated non-LB
risk assessment algorithms will enable health care providers in resource constrained
settings to initiate risk reduction discussion and interventions within one clinical visit. It
has been estimated that an individual’s absolute risk score can be calculated within five to
ten minutes using these algorithms because the only data required to estimate absolute
risk include: age, BMI, systolic blood pressure, antihypertensive medication use, current
smoking, and diabetes status (D'Agostino RB et al., 2008; Gaziano et al., 2008). This
point of care utility may add great value in underserved populations which are difficult to
follow.
The proposed use of the non-LB Framingham algorithm, which was derived in a
population that was 99.7% white, raises issues of applicability in black populations.
Whereas poor performance of Framingham based algorithms has been reported in certain
ethnicities (e.g. Hispanics), the models have performed reasonably well in predicting
CVD in the US black population (Beswick et al., 2008).
The adoption of algorithms developed in significantly different settings and
populations is traditionally done under the assumption that the major risk factors for
CVD are fairly similar around the world (Yusuf et al., 2004). The INTERHEART
investigators delineated 9 major risk factors (smoking, lipids, hypertension, diabetes,
obesity, unhealthy diet, physical inactivity, harmful alcohol consumption, and
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psychosocial factors) which account for over 90% of the population attributable risk of
acute myocardial infarction worldwide (Yusuf et al., 2004).
Summary
Validating and costing the non-LB Framingham algorithm could make an
important contribution to the ongoing efforts to address the high burden of CVD in
underserved communities especially the US black population. The challenges discussed
in this review including the problem of limited access to healthcare due to location and
lack of health insurance can be mitigated by availability of a valid and cost-effective risk
assessment algorithm.
Such an algorithm can be deployed at the point of service in real time, without
need for follow-up visits to draw laboratory specimens or to review results. The time
utility would make every visit in the resource constrained settings an opportunity to
initiate risk reduction discussion, and to motivate adherence and self-management since
the data required is readily collected during the office visit. To improve the effectiveness
of CVD prevention while using the non-LB Framingham algorithm, individuals with
borderline or indeterminate risk may then be further screened using the more resource
intensive laboratory measures whenever feasible.
Chapter 3 focuses on research design and methodology used in the external
validation and cost-effectiveness analysis.
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CHAPTER 3
RESEARCH DESIGN AND METHODS
Overview
To address the specific aims of the project, a secondary data analysis was
conducted using the ARIC dataset. The dataset is organized in four cohorts, three of
which are predominantly or completely white (Forsyth County, NC; Suburbs of
Minneapolis, MN; and Washington County, MD) while one cohort (Jackson, MS) is
composed of black participants (ARIC Investigators, 1989). This diversity facilitated an
adequately powered sub-analysis of the performance of the tool in the black sample.
Data Source and Design
The ARIC study is a prospective epidemiologic study with an overarching goal to
investigate the etiology and natural history of atherosclerosis and its clinical sequelae,
and examine the distribution of cardiovascular risk factors, medical care, and disease by
race, sex, living location, and time. The study includes cohort and community
surveillance components conducted in four ARIC field centers that include Forsyth
County, NC; Jackson, MI; Minneapolis, MN and Washington County, MD. The Cohort
Component of the study commenced in 1987, with each ARIC field center using driver
license lists to randomly select about 4,000 individuals aged between 45-64 years from a
defined population in their community (ARIC Investigators, 1989).

22

A total of 15,792 individuals were recruited, but the ARIC dataset provided by the
NHLBI included 15,053 adults who had no missing variables on the identification
variable. Before the eligibility criteria was employed, the dataset included a total of 8,163
women (54%) and 3,898 blacks (26%) aged 45-64 years. The sample was organized in
four cohorts based on the ARIC field centers described earlier and all participants were
examined at baseline between 1987 and 1989, followed by three more site-based
examinations which ended in 1998. Yearly telephone follow-up interviews continue as a
way to maintain contact with participants and to assess the health status of the cohort.
Details of the examination procedures and criteria for the endpoints assessed have been
reported elsewhere (ARIC Investigators, 1989). Table 1 summarizes sample
characteristics, how essential risk factors relevant to this study were assessed, and CVD
related endpoints monitored.
This secondary data analysis focused on the first 12 years of follow-up after
baseline examination in ARIC. Therefore, this study’s sample consists of study
participants who attended baseline examination (1987-1989) and who at baseline were
free of CVD, aged 45 to 64 years, and with no missing data on the variables of interest
either at baseline or follow-up assessments in the next 12 years. The sample meeting
these eligibility criteria includes 11,601 participants as described in Figure 2.
The 12 years follow-up employed in this study matches the follow-up time used
by (D'Agostino RB et al., 2008) when generating the non-LB and LB Framingham
algorithms. This congruence of follow-up time will increase comparability of the
performance of the algorithms in ARIC and Framingham datasets. The covariates
required to validate the non-LB Framingham algorithm include age, sex, and diabetes
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status, smoking status, blood pressure, hypertension treatment and body mass index. The
end points that are necessary to evaluate the calibration of the tool include the confirmed
diagnosis of coronary artery disease, cerebrovascular disease, peripheral arterial disease
and heart failure. Table 1 compares key aspects of the non-LB and LB Framingham
algorithms and their derivation dataset, with the ARIC dataset in regard to design,
sampling, assessments, data collected at baseline and the endpoints monitored. The costeffectiveness analysis focused on the black subset of the ARIC dataset who met the
eligibility criteria described above.

Figure 2: Flowchart of inclusion and exclusion criteria and monitored outcomes

15,053 participants (26% Black, 54% Female) of the ARIC baseline exam
(1987-1989)

Ineligibile: 3,452 (23%)
*609 (18%) from Minneapolis, MN
*889 (26%) from Washington, MD
*1,052 (30%) from Jackson,MS
*799 (23%) from Forysth,NC
*103 (3%) cohort location missing

(A) Minneapolis, MN
3,217 (100% White)

1,545 incident
CVD events in
the entire ARIC
cohort (13.32%)

(B) Washington, MD
2,893 (100% White)

(C) Jackson, MS
2,381 (100% Black)

11,601 (23% Black)
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(D) Forysth, NC
3,110 (10% Black)

401 incident
CVD events in
the black ARIC
cohort (14.91%)

Baseline assessment
In the ARIC cohort, the baseline examination commenced with participants
giving informed consent. The baseline examination assessed CVD conditions and
measured key athrogenic risk factors. Key elements of the interview included the
assessment of angina (Rose Questionnaire), history of diabetes, transient ischemic attack,
and peripheral arterial disease, smoking status and medications use. Positive history was
verified by laboratory test results and/or in the medical records abstracted by nurse
researchers (ARIC Investigators, 1989).
Blood pressure was measured with the participant seated, with feet on the floor
and arm at heart level, with three readings 5 minutes apart using random zero
sphygmomanometer. The average of the second and third systolic blood pressure is
entered into the model as a continuous variable. Anthropometric measurements were
made with the participants wearing light-weight; non-constricting underwear, after
emptying the bladder. Height and weight measurements were taken with the participant
in light clothing and not wearing shoes. BMI was calculated as a function of height in
meters and weight in kilograms, and was entered into the model as a continuous variable
(ARIC Investigators, 1989).
Diabetes was operationalized by two variables in the ARIC study. The DIABTS03
variable defined diabetes as fasting glucose greater or equal to 126 mg/dL, and use of

insulin or oral hypoglycemic medications, while the DIABTS02 variable applied a similar
definition but used a fasting glucose level greater or equal to140mg/dL. Fasting glucose
in both variables was measured during the scheduled baseline assessment, after at least 8
hours of fasting. Sex and smoking status were ascertained based on self-report and
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entered as dichotomous variables, while antihypertensive medication use was determined
through self-report and medication review as described in Table 1 (ARIC Investigators,
1989).
Similar protocols were used to measure covariates in the Framingham cohort,
with the exception of diabetes whereby fasting glucose greater or equal to 126mg/dL was
used as the threshold for diabetes in the Framingham offspring cohort, and greater or
equal to 140mg/dL as the threshold for the original cohort (D'Agostino RB et al., 2008).
In this analysis, we used DIABTS03 as the dichotomous variable indicating presence or
absence of diabetes since it includes both thresholds used in the original and offspring
cohorts of the Framingham study. Table 1 compares how selected sample characteristics,
covariates and end points were assessed in the Framingham versus ARIC datasets.
Follow-up Assessments
All study participants were under continuous sentinel surveillance for the
development of CVD events and death. The average follow-up response rate at year 12
was 95.68%, will all cohorts having response rates greater than 93% (University of North
Carolina at Chapel Hill, 2013). After the baseline examination, a telephone questionnaire
was administered annually, including the Rose angina questionnaire (screens for angina)
and items on general health and hospitalization. Events of interest during follow-up
included hospitalized and non-hospitalized myocardial infarction, coronary heart disease
death, angina pectoris, stroke, and intermittent claudication (ARIC Investigators, 1989).
However, the events included in the secondary dataset provided by National Heart Lung
and Blood Institute (NHLBI) included; coronary artery and cerebrovascular disease, atrial
fibrillation or flutter and heart failure.
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In this analysis general CVD events include coronary heart and cerebrovascular
disease, and heart failure. Atrial fibrillation and flutter were not included since they were
not included in the Framingham cohort outcomes, while peripheral vascular disease
outcomes were not availed in the ARIC dataset provided by the NHLBI (see Table 1).
The cardiovascular events were ascertained through annual follow-up
questionnaires, physical examinations at the study sites, communication with personal
physicians and surveillance of medical records. Suspected new events were
independently confirmed through review of medical charts by three experienced
investigators, and neurological events were confirmed by a neurologist. Hospital records
were abstracted twice independently by nurse abstractors to monitor CVD events; all
substantive discrepancies were reconciled. Cardiac enzyme levels were recorded three
times one day after the event, and two times for each of the next three days. The reviewed
cardiac enzymes included: lactate dehydrogenase, lactate dehydrogenase subfractions,
and creatinephosphokinase. Three serial electrocardiograms were reviewed, coded and
interpreted at the University of Minnesota ECG Center using the full Minnesota code
(ARIC Investigators, 1989).
Underlying and contributory causes for all deaths of cohort members were also
investigated to determine whether the cause was CVD. Where death occurred in a
hospital, the hospital record was used, but if the decedent had died outside the hospital,
family interviews, physician questionnaires, and coroner records were used (ARIC
Investigators, 1989).
The endpoints monitored in ARIC study follow-up closely correlate with the end
points used in the internal validation of the non-LB and LB Framingham algorithm which
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included coronary events (coronary death, myocardial infarction, coronary insufficiency,
and angina), cerebrovascular events (ischemic stroke, hemorrhagic stroke, and transient
ischemic attack), peripheral artery disease (intermittent claudication), and heart
failure.(D'Agostino RB et al., 2008) This congruence of protocols for assessing risk
factors and endpoints (with exception of failure to include peripheral vascular disease in
ARIC) enables rigorous external validation of the algorithm (see Table 1). Costeffectiveness measures are discussed separately in the analysis strategy under hypothesis
3 and 4.
Statistical Analyses
The sex-specific non-LB Framingham algorithm was developed using sexspecific Cox proportional-hazards regression models (Cox regression). The covariates
included in the model, which were also measured in the ARIC dataset, entail; age,
systolic blood pressure, antihypertensive medication use, current smoking, BMI, and
diagnosis of diabetes mellitus (D'Agostino RB et al., 2008). To ensure coherence and
rigor of the external validity analysis, the same regression model and covariates were
used in the secondary analysis of the ARIC dataset since the necessary inputs were
available in the dataset.
Continuous variables (covariates) were transformed into natural logarithms to
improve discrimination and calibration of the model and to minimize influence of
extreme observations. Specific data on the exact days to incident CVD events since
baseline examination, which are essential when using Cox regression, were included in
the ARIC dataset. The incident CVD dates were ascertained through the rigorous followup methods detailed above, including systematic tracking of medical records and personal
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communication with physicians since the participants had consented to these disclosures
(ARIC Investigators, 1989).
Cox regression allowed evaluation of the effect of various independent variables
on the time at which a specified event occurs without making assumptions on the baseline
hazard. Cox regression was used in the survival analysis after all the covariates included
in the models met the proportionality of hazards assumption (Cleves, 2008). The
assumption required; a) all continuous predictors such as systolic blood pressure to have
a constant effect on survival across all analysis groups during the entire period of followup; b) categorical predictors (e.g. smoking status) to have the same shape of hazard
function within each analysis group during the entire period of follow-up.
Analysis plan by study aims
Specific aim 1: Assess the accuracy of the non-LB Framingham algorithm in
stratifying risk and predicting CVD events in a racially diverse population.
Hypothesis 1: Non-LB Framingham algorithm will have adequate discrimination
(Harrell’s C statistic greater than 0.75) and calibration (Hosmer-Lemeshow goodness of
fit (χ 2) below 20) in the multiracial ARIC dataset.
This hypothesis was tested by evaluating the frozen sex-specific non-LB
Framingham algorithm’s ability to: a) accurately stratify risk (discrimination) for persons
who experienced a CVD event and those who did not, and b) predict CVD events
(calibration), in the ARIC dataset. Discrimination (the ability of a risk prediction tool to
assign a higher risk to those who will develop the end points of interest compared to
those who will not) was measured using Harrell’s C statistic and AUROC curve.
Adequate discrimination was demonstrated by an overall C statistic of 0.75 or higher as
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recommended in the literature (Cooney et al., 2009; May et al., 2006). In addition,
sensitivity (proportion of individuals with CVD events who were predicted as high risk)
and specificity (proportion of individuals without CVD events who are not predicted as
high risk) of the tool was calculated using the roctab command in Stata©.
Calibration of the mathematical models was assessed by measuring the
concurrence between the predicted outcomes and observed outcomes using HosmerLemeshow goodness of fit statistic (χ 2). Kaplan-Meier survival analysis was used to
obtain the observed incidence of CVD events, which was then be compared with the
CVD events predicted by the non-LB Framingham algorithm. Kaplan-Meier method was
preferred in this analysis because it allowed estimation of survival over time, even when
some participants were censored or had varying lengths of follow-up. A HosmerLemeshow goodness of fit (χ 2) statistic below 20 was considered a good fit as
recommended in literature (Cooney et al., 2009).
The frozen Framingham model and algorithm was compared by one generated
using ARIC data. In addition, re-calibration of the Framingham model using ARIC’s
baseline survival and risk factor means was done and new recalibrated model and
algorithm developed for comparability in discrimination and calibration (D'Agostino RB,
Grundy, Sullivan, Wilson, & CHD Risk Prediction Group, 2001a). In this study, the
frozen Framingham algorithm refers to the unaltered Framingham algorithms with
baseline survival, regression coefficients and mean of risk factors as published by D
’Agostino and colleagues (D'Agostino RB et al., 2008).
Specific aim 2: Compare the performance of the non-LB Framingham algorithm
in the black versus white participants of the ARIC study.
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Hypothesis 2: There will be no significant difference in discrimination and
calibration of the non-LB Framingham algorithm between the black and white
participants of the ARIC study.
After validating the sex-specific non-LB Framingham algorithm in the entire
ARIC cohort, a sub-analysis was conducted to assess the performance of the tool in the
black and white cohorts. This analysis examined the ability of the tool to accurately
predict CV risk in each racial subgroup stratified by sex. The Statistical analyses
approach described under hypothesis 1 were used to conduct the sub-analysis by race.
Re-calibration was done by substituting Framingham baseline survival and risk factor
means with race specific baseline survival and risk factor means in the ARIC dataset. All
the non-LB models were compared with their LB counterparts using AUROC analysis
and agreement using kappa statistic. The kappa-statistic is measure of inter-rater
agreement, which is 0 when agreement is random and 1 when agreement is perfect.
Cost-effectiveness analysis
Specific aim 3: Establish the feasibility of using the non-LB Framingham
algorithm in guiding prevention of CVD among the black participants enlisted the ARIC
study.
Hypothesis 3: A CVD prevention strategy guided by the non-LB Framingham
algorithm will be more cost-effective compared with treating each elevated CVD risk
factor (diabetes and/or hypertension) independently in the black subset of the ARIC
cohort.
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Hypothesis 4: A CVD prevention strategy guided by the non-LB Framingham
algorithm will be more cost-effective compared with a strategy guided by the LB
Framingham algorithm in the black subset of the ARIC cohort.
This analysis compared the cost-effectiveness of a CVD prevention strategy
guided by absolute CVD risk estimates, calculated using the non-LB and LB
Framingham algorithms, visa-vis an approach based on treating each elevated CVD risk
factor (diabetes and/or hypertension) independently in the black subset of the ARIC
cohort.
Although there are seven major risk factors for CVD that are modifiable, only two
were included in costing the approach based on treating individual CVD risk factors.
Hypertension and diabetes were selected due to their strong association with CVD and
their significance in the global public health agenda. Hypertension is the leading cause of
CVD worldwide, and diabetes is known to double the risk of CVD events (S. Mendis et
al., 2011).
The thresholds for initiating therapy and treatment modalities in the individual
risk factors approach e based on recommendations from the American Society of
Hypertension and International Society of Hypertension (ASH-ISH) guidelines for
management of hypertension, and the International Diabetes Federation (IDF) guidelines
for management of diabetes (IDF Clinical Guidelines Task Force, 2006; Weber et al.,
2014). The guidelines were selected for costing due to their primary focus on either
diabetes or hypertension, and their international applicability. The essential components
of these guidelines relevant to this analysis are discussed below and summarized in
Figure 3.
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According to the ASH-ISH guidelines, hypertension is defined as systolic blood
pressure greater or equal to 140 mmHg or diastolic blood pressure greater or equal to 90
mmHg or both. The guidelines recommend timing and tailoring the intensity of treatment
based on the stage of hypertension. Stage 1 hypertension is defined as systolic blood
pressure below 160 or diastolic blood pressure below 100, while stage 2 hypertension
denotes blood pressures above these thresholds. Monotherapy with a calcium channel
blocker (e.g. Amlodipine) or a thiazide diuretic (e.g. Hydrochlorothiazide) is
recommended for blacks with stage 1 hypertension irrespective of their diabetes status,
while addition of a second agent (angiotensin-converting enzyme (ACE) inhibitor in
diabetes) is recommended in stage 2 hypertension as outlined in Figure 3.
In resource constrained settings, the guidelines recommend use of lifestyle
modification for up to one year before starting drug therapy in stage 1 hypertension when
no other CVD risk factors are present. All treatment modalities are focused on attaining
targets below the diagnostic threshold but no explicit follow-up regimen is provided by
the ASH-ISH guidelines (Weber et al., 2014).
The IDF guidelines defines diabetes as fasting blood sugar greater than 7 mmol/l
(126mg/dL) or random blood sugar above 11.1mmol/l (200mg/dL). Treatment options
are graded from first-line to fourth-line therapy depending on attainment of glucose
control targets. First-line therapy includes monotherapy with a biguanide (e.g.
Metformin) or an equivalent agent, while second-line therapy adds a sulfonylurea (e.g.
Glipizide) or an equivalent agent as summarized in Figure 3. Addition of a third agent,
such as a-glucosidase inhibitor, or starting insulin treatment constitutes third-line therapy.
If glucose control targets are not achieved with third-line therapy, insulin treatment is
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initiated alongside oral hypoglycemic agents as part of fourth-line therapy. The
guidelines also recommend use of statins (based on lipid levels) to reduce risk of CVD
events and periodic monitoring of glycated hemoglobin (HbA1C) as part of a
comprehensive management program (IDF Clinical Guidelines Task Force, 2006). A
follow-up regimen is not explicitly stipulated. Figure 3 outlines risk stratification and the
basic preventive interventions prescribed by the approach guided by treating individual
CVD risk factors.
Figure 3: CVD prevention strategy based on treating diabetes/hypertension to target goals
Screen for hypertension & diabetes

High risk for
CVD (presence of
DM and/or HTN)

High risk for CVD
due to DM:
Hx/Rx of diabetes/
FBS>7mmol/l or
RBS>11.1mmol/l
Monotherapy for
initial rx of
uncomplicated DM
(preferably with
Metformin)

Titrate dose or add
second agent (e.g.
Glipizide if
suboptimal glucose
control on f/u

Low risk for CVD
(absence of DM
and HTN)

High risk for CVD
due to HTN:
Hx/Rx of HTN or
BP ≥140/90mmHg

Monotherapy if BP
≥140/90mmHg
(CCB or Thiazide in
Blacks)

Lifestyle
management

Combined therapy
if BP
≥160/100mmHg
(CCB +Thiazide or
ACEI in DM)

CVD prevention strategy based on treating diabetes and hypertension to target goals adapted from ASHISH and IDF guidelines (IDF Clinical Guidelines Task Force, 2006; Weber et al., 2014)

The absolute risk approach to CVD prevention is recommended by major CVD
management guidelines based on the premise that whereas individual risk factors
independently increase the likelihood of CVD events, clustering of multiple risk factors is
known to compound the CVD risk (Beswick et al., 2008). Guidelines adopting the
absolute risk approach to CVD prevention tailor the choice and intensity of recommended
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treatments based on absolute CVD risk scores calculated using CVD risk assessment
algorithms, such as the non-LB Framingham algorithm externally validated in this study.
The 2007 CVD prevention guidelines by the WHO were selected as the basis for
costing interventions associated with the absolute risk approach due to their congruence
with Framingham algorithms and relevance to primary prevention of CVD. Interventions
recommended by the WHO guidelines (see Table 2) are based on absolute risk scores for
general CVD events including coronary heart disease, peripheral vascular disease and
cerebral vascular disease (World Health Organization, 2007). Both the non-LB and LB
Framingham algorithms validated in this study were developed to predict these general
CVD events, these are broader outcomes than the hard coronary events predicted by
earlier versions of Framingham (D'Agostino RB et al., 2008). Currently there are no
feasible alternatives to the WHO guidelines since the American Heart Association CVD
prevention guidelines are dated (published in 2002) and limited by their narrow focus on
hard coronary events (Pearson et al., 2002).
The WHO CVD prevention guidelines organize their recommended preventive
interventions in four categories based on absolute CVD risk scores as follows; low risk
(>10%), moderate risk (10% to 20%), high risk (20% to 30%) and very high risk >30%.
Table 2 outlines the four risk categories and the treatment options recommended for each
(World Health Organization, 2007). According to these guidelines, an individual with an
absolute risk score >30% is: a) scheduled for follow-up visits at least every 6 months, b)
started on antihypertensive therapy (if blood pressure is greater or equal to
130/80mmHg), c) started on a statin, d) put on glucose lowering therapy (if fasting blood
sugar is equal or greater than 7mmol/l), and e) started on low dose aspirin therapy.
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Table 2: WHO choice & intensity of CVD prevention strategy guided by absolute CVD risk
Absolute CVD risk
> 30% (very high)

Absolute CVD risk
20-30% (high)

Absolute CVD risk
10-20% (moderate)

Absolute CVD risk
<10% (low)

Monitor risk profile
every 3-6 monthsa,b

Monitor risk profile
every 3-6 monthsa,b

Monitor risk profile
every 6-12 monthsa,b

Conservative lifestyle
modificationa,b

Treat BP≥160/100 with
recommended drugsc

Treat BP≥160/100 with
recommended drugsc

Treat BP ≥160/100
with recommended
drugsc

Treat BP ≥160/100 with
recommended drugsc

Treat persistent BP
≥130/80 with
recommended drugsc

Treatc persistent BP
≥140/90 unresponsive
to lifestyle for 4-6mo

Lifestyle mx for
persistent BP≥140/90
reassess annually

Lifestyle mx for
persistent BP≥140/90
reassess q2-5yrs

Treat with a statin and
a lipid-lowering diet

Lipid lowering diet;
add statin if TCd
>5mmol/l & >40yrs

Lipid lowering diet;
add statin if TCd
>8 mmol/l

Lipid lowering diet; add
statin if TCd
>8 mmol/l

Glucose lowering
therapy (Metformin)
for persistent FBS> 7
mmol/l

Glucose lowering
therapy (Metformin)
for persistent FBS> 7
mmol/l

Glucose lowering
therapy (Metformin)
for persistent FBS> 7
mmol/l

Glucose lowering
therapy (Metformin) for
persistent FBS> 7
mmol/l

Low dose Aspirin

Aspirin not generally
recommended

Aspirin not
recommended

Aspirin not
recommended

CVD prevention strategy based absolute risk score, adapted from the WHO CVD prevention guidelines (World
Health Organization, 2007).
Key: TC (total cholesterol); FBS (fasting blood sugars)
a
Smoking cessation and lifestyle management recommended across risk profiles
b
Abstaining or reducing alcohol intake to <3units per day recommended across risk profiles
c
First line antihypertensive therapy includes: thiazide-like diuretic, ACE inhibitor, calcium channel blocker
d
Measures of TC may not be accessible in resource constrained regions.
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Case example: individual vs absolute CVD risk approach
The differences between the individual risk factors approach and the absolute risk
approach to CVD prevention are evident in the treatment modalities recommended in
Figure 3 and Table 2 for each strategy respectively. A case example is Mr. Q, a 57 years
old male, who is a smoker with no history of diabetes or hypertension. He presents with
a blood pressure of 138/88 mmHg, fasting blood sugar of 6 mmol/l (108mg/dL), HDL of
1.16 mmol/l (45mg/dL), total cholesterol of 5.84 mmol/l (226 mg/dL) and a BMI of 26.
If the individual risk factors approach outlined in Figure 3 was used to manage
Mr. Q, only lifestyle modification, with emphasis on smoking cessation, would be
recommended since he does not meet the hypertension threshold specified by the ASHISH guidelines or the threshold for diabetes recommended by the IDF guidelines.
If the absolute risk approach was used to manage Mr. Q, he would have an
absolute CVD risk score of 30.4% and 30.1% according to the online interactive non-LB
and LB Framingham absolute CVD risk calculators respectively (D’Agostino & Pencina,
2016). These absolute CVD risk calculators use the general formulae for predicting CVD

events outlined in the literature review section. The general formulae combine sundry
CVD risk factors to calculate the probability of a CVD event occurring within a
maximum time frame of 12 years.
Mr. Q absolute CVD risk score is very high despite apparently normal or near
normal individual risk factors because the score appreciates the additive nature of subtle
elevations in CVD risk factors (e.g. blood pressure, BMI and total cholesterol).
Consequently, in addition to lifestyle modification, the absolute risk approach based on
either the non-LB or LB Framingham algorithm absolute risk score will prescribe Mr. Q
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the relevant interventions under the “very high risk category” (>30%) in Table 2. The
relevant interventions for Mr. Q would include: follow-up visits at least every 6 months,
antihypertensive therapy (since BP>130/80mmHg), statin therapy, and low dose aspirin.
Absolute versus individual risk decision model
In order to fully appreciate the differences between the individual risk factors and
absolute risk approaches to CVD prevention, the black cohort in ARIC was stratified by
the type of screening algorithm used in the preventive approach. The different categories
for each CVD prevention approach are summarized in Figure 4.1 and detailed below.
When the individual CVD risk factor approach was employed (lower arm in
Figure 4.1), the black cohort free of CVD at baseline was stratified into high and low
CVD risk categories depending on presence or absence of diabetes and/or hypertension.
The true and false high risk categories were both prescribed the intensive preventive
interventions outlined in Figure 3, while the true and false negatives were prescribed
lifestyle management. The false positives ended up receiving unnecessary intensive
treatment, while the false negatives missed essential treatment culminating in CVD
events. In the simulated analysis, a high number of false positives were expected to
increase level II expenses, while a high number of false negatives would increase level III
expenses due to treatment and rehabilitative costs associated with CVD events that occur
as a result of missing preventive interventions.
When the absolute CVD risk approach was employed guided by either the nonLB or LB Framingham algorithm, the black cohort free of CVD at baseline was stratified
into four CVD risk categories based on their absolute risk score. When a specific risk
category was selected as the threshold for initiating treatment based on
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sensitivity/specificity analysis, individuals below the threshold were assumed to be low
risk, while those above the threshold were considered high risk and put under the
treatments prescribed for their respective category.
For instance, if the moderate risk category (10-20%) in Figure 4.1 was set as the
treatment threshold, the sample with absolute risk score below 10% would be exempted
from treatment, while individuals in other risk categories would receive the appropriate
therapy based on their risk sore as outlined in Table 2. As a result, the false positives
receive unnecessary treatments and increase level II expenses, while the false negatives
miss essential preventive treatments culminating in CVD events which incur level III
treatments outlined in Figure 4.1.
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Figure 4.1: Event trajectories associated with three CVD prevention strategies

Level II Costs
Fatal CVD
events
Very high
absolute risk
(≥30%)

True very
high

Very intensive
preventive
interventions

False very
high

Level I Costs

High
absolute risk
(20-30%)

True high

CVD
events
CVD free

Intensive
preventive
interventions

Non-CVD
deaths

False high

Level III Costs
Assess absolute
CVD risk (using
non-LB or lab
based
Framingham)

CVD free Blacks
in the ARIC
cohort at baseline
(visit 1)

True
moderate

Moderate
absolute risk
(10-20%)

Moderate
preventive
interventions

False
moderate
True low

Low
absolute risk
(<10%)

Fatal/non-fatal
CHD
Heart Failure
Stroke

Lifestyle
management

False low

Fatal CVD
events
CVD
events

Screen for two
major CVD risk
factors (DM ±
Hypertension)

High risk
(prevalent DM
± hypertension)

True high
risk

Treatment for
DM ±
hypertension

Non-CVD
deaths

False high
risk
Low risk (free
from DM and
hypertension)

True low
risk
False low
risk
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CVD free

Lifestyle
management

Cost-effectiveness framework
The incremental cost effectiveness tested under hypothesis 3 and 4 was done
under the framework of the cost-effectiveness model below adapted from the methods
described by Drummond for evaluating incremental costs and effects of a program
(Drummond & Drummond, 2005). To adapt the equation for hypothesis 4, the individual
risk factors (r) approach was substituted with the LB Framingham (l) approach).
The incremental cost effectiveness ratio (ICER) model:

ICER =

∆TCa−r

=

2
𝑡
t=12
1 j=1 [CRxajt +CUSEajt –CRxrjt −CUSErjt ]/(1+d)

2
𝑡
∆Ea−r
t=12
1 j=1 [CVDajt – CVDrjt ]/(1+d)
ICER model Key:
 ICER = incremental cost-effectiveness ratio
 TCa – r = the discounted difference between the total costs incurred in 12 years to
manage CVD in the absolute (a) versus the individual risk factors (r) approach.
 Ea – r = the discounted difference between true positives predicted in the absolute (a) vs.
the individual risk factors (r) approach.
 CRxajt, CRxrjt = the discounted cost of preventive interventions (see Table 2) prescribed to
the j-th risk group predicted by absolute (a) versus by individual risk factors (r) approach
in year t (same for CRxrjt, use Figure 3).
 CUSEajt, CUSErjt = the discounted cost of treating 3 major CVD events occurring (false
negatives in Figure 4.1) in the j-th risk group associated with absolute (a) vs individual
risk factors (r) approach in year t (same for CUSErjt)
 CVDajt-CVDrjt = the discounted difference between true positives predicted in the j-th
absolute or individual risk factors group in year t.
 d = 3% discount rate as recommended by the US Panel on Cost-Effectiveness in Health
and Medicine (Weinstein, Siegel, Gold, Kamlet, & Russell, 1996).
Each preventive approach was costed on three levels as outlined in Figure 4.1. Level I

expenses includes screening costs, level II expenses included the cost of preventive
interventions prescribed in Table 2 for the absolute risk approach, and Figure 3 for the
individual risk factors approach, while level III expenses included the cost of treating
CVD events that occurred in the false negative group. Outcomes in this analysis included
three CVD events (fatal and non-fatal CHD, heart failure, and stroke) expected to be
prevented over 12 years after implementation of each preventive strategy. The sum of
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level I and II expenses constituted CRx, while level III expenses were represented by
CUSE in the ICER model. All costs and outcomes were discounted at the rate of 3% as
recommended by the US Panel on Cost-effectiveness in health and medicine (Weinstein
et al., 1996).
Discounting refers to the practice of weighting future gains and losses less heavily
than those that occur in the present. The concept is based on the premise that a dollar or a
life is worth more today that it would be in the future (Smith & Gravelle, 2001). In this
analysis, discounting is used to estimate the present value of future costs and CVD events
associated with each of the three CVD prevention programs.
Interpreting the ICER
The incremental cost-effectiveness ratio was interpreted using a cost-effectiveness
plane adapted from Drummond (Drummond & Drummond, 2005). In this analysis, the
existing programs were considered to be the individual risk factors and LB absolute risk
approaches to CVD prevention, while the new program was considered to be the non-LB
absolute risk approach. In the plane outlined in Figure 4.2, an ideal ICER ratio would be
a more effective and less costly new program as depicted in the lower right quadrant. The
ratio could also be acceptable if the new CVD prevention program is slightly less
effective but way less costly (see left lower quadrant), or more expensive but highly
effective compared to the existing programs (see right upper quadrant). An expensive but
less effective program is unacceptable under all circumstances. At origin, the new
program is similar in costs and effects with the existing program.
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Figure 4.2: Cost-effectiveness plane depicting acceptability of ICER ratios
New program
more costly

Ability to pay
for marginal
effectiveness
New program
more effective

New program
less effective
Cost vs
effectiveness
trade-off

Acceptable
ICER

New program
less costly
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CHAPTER 4
RESULTS
The external validation described in this chapter entails evaluation of
mathematical performance and applicability of the Framingham non-LB algorithms in the
ARIC dataset. Mathematical performance is evaluated by reproducing the underlying
Framingham mathematical models in ARIC and comparing their regression coefficients,
discrimination and calibration with those derived in the Framingham dataset.
Applicability of the Framingham algorithms in ARIC is evaluated by comparing the
AUROC’s and sensitivity/specificity ratios of CVD risk stratification based on the
published Framingham algorithms versus other models generated in the ARIC dataset.
This chapter is organized in five parts to address; a) description of the ARIC
sample baseline characteristics and incident CVD events, b) mathematical performance
of the Framingham models in ARIC dataset, c) performance of the Framingham
algorithms in the ARIC sample, d) sensitivity/specificity analysis of the algorithms
applied to predict risk in the ARIC sample, and e) simulated cost-effectiveness analysis
of the non-LB Framingham algorithm in the black cohort of the ARIC sample.
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a) Sample description
This section describes the baseline characteristics of the eligible and ineligible
sample based on the criteria discussed in the methods section, and the observed
incidence of CVD events within the 12 years of follow stratified by sex and race.
Sample characteristics
The ARIC dataset provided by the NHLBI consisted 15,053 participants who
completed the ARIC baseline exam between 1987 and 1989. Twenty-six percent of these
participants were black and 55% were female. When the eligibility criteria described in
the methods section were applied, 23% (3,452) of the original ARIC cohort was
excluded. Therefore, the sample in this study includes 11,601 participants (23% black,
55% female).
The baseline characteristics of the eligible and ineligible sample are described in
Table 3.1. Overall, 82% of those excluded had CVD at baseline examination. When the
eligible sample was stratified by sex, men had a higher profile of CVD risk factors
(diabetes, hypertension, smoking, HDL and total cholesterol) compared to women except
for BMI and diabetes. Table 3.2 outlines the variables of interest stratified by gender.
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Table 3.1: Baseline characteristics stratified by eligibility criteria

N
Male (n, %)
white (%)
Age (mean, sd)
Diabetes (n, %)
Current smoker (n, %)
BMI (mean, sd)
SBP (mean, sd)
Hypertension (n, %)
BP treatment (n, %)
HDL (mean, sd)
Total chol (mean, sd)
Baseline CVD (n, %)

Eligible

Ineligible

P (95% CI)

11601
5246 (45.22)
8911 (76.81)
53.91 (5.74)
1152 (9.93)
2970 (25.60)
27.39 (5.14)
120.27 (17.99)
3,866 (33.32)
2775 (23.92)
52.15 (17.08)
214.21 (41.05)
0 (0)

3452
1541 (46.01)
2141 (63.93)
55.43 (5.69)
658 (20.48)
990 (29.69)
28.84 (5.96)
125.35 (21.90)
2116 (64.28)
1858 (55.61)
48.92 (16.93)
218.19 (45.36)
2801 (81.52)

0.417
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

Baseline characteristics recorded at the baseline exam for entire ARIC cohort between 1987 and 1989
Data presented as mean/SD for continuous variables and as frequencies (%) for categorical variables
Chi2 and t test were used as the tests of homogeneity for categorical and continuous variables respectively

Table 3.2: Baseline characteristics of the eligible sample stratified by sex and race
White
female

Black
female

N

4758

1597

Diabetes ( %)

6.85

18.79

Current smoker (%)

24.88
26.3 (5.2)

BMI (mean, sd)
SBP (mean, sd)

p

White
male

Black
male

4153

1093

0.000

8.72

15

0.000

23.67

0.329

24.01

37.60

0.000

30.6 (6.3)

0.000

27.3 (3.9)

27.5 (4.9)

0.213

116.4 (17.4) 126.5 (19.5) 0.000

120 (15.8)

129 (20.1)

0.000

(95% CI)

p
(95% CI)

Hypertension (%)

27.87

53.73

0.000

26.99

51.33

0.000

BP treatment (%)

21.21

42.08

0.000

18.28

30.65

0.000

HDL (mean, sd)

58 (17)

58.3 (17.3)

0.525

43.2 (12.4)

51.3 (17.2)

0.000

217.4 (41.4) 216.5 (44.4) 0.464

210.3 (38)

211.6 (43.1)

0.319

Total chol (mean, sd)
Age (mean, sd)

53.8 (5.7)

53.1 (5.8)

0.000

54.4 (5.7)

53.5 (6)

0.000

Intermediate educ. (%)

51.16

29.59

0.000

39.43

26.72

0.000

Advanced educ. (%)

33.85

32.79

0.000

44.61

31.22

0.000

Baseline characteristics recorded at the baseline exam for entire ARIC cohort between 1987 and 1989
Data presented as mean/SD for continuous variables and as frequencies (%) for categorical variables
Chi2 and t test were used as the tests of homogeneity for categorical and continuous variables respectively
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Incident CVD during 12 years of follow-up
During the 12 years of follow-up included in this analysis 1,545 new cases of
CVD occurred in the eligible ARIC cohort comprised of 11,601 individuals. This
translated into 11.1 incident CVD cases per 1000 persons-years. Stratified by sex and
race, the incidence rate among white versus black women was 6.5 versus 10.2 cases per
1000 person-years respectively, and 15.5 versus 15.6 cases per 1000 person-years among
white versus black men respectively.
white and black men had the highest incidence rate of CHD (12.1 and 9.0 cases
per 1000 person-years respectively), while black and white women had the lowest
incidence (4.3 and 3.7 per 1000 person-years respectively). The incidence of heart failure
was highest among black women and men (5.4 and 5.2 cases per 1000 person-years
respectively), while white men and women had the lowest incidence (4.6 and 2.7 cases
per 1000 person-years respectively). The incidence of stroke was highest among black
men and women (4.7 and 3.9 case per 1000 person-years respectively). White men and
women incidence of Stroke was low at 2.4 and 1.4 cases per 1000 person-years
respectively. Figure 5 shows the incidence rate of general and cause specific CVD events
stratified by sex and race.
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Figure 5: General & cause specific CVD incidence rate in ARIC stratified by sex & race
CVD incidence rate stratified by race & sex
18

Incidence rate per 1000 person-yrs
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9.0
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6
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3.7

4

5.2
4.7

4.6

4.0

Black men

3.9
2.7

2

2.4

White men

2.4
1.4

0

General CVD

CHD

Heart failure

Stroke

Data source: ARIC 1987-1999

The incidence proportion of CVD during the 12 years of follow-up was 13.3% in
the entire ARIC cohort. Stratified by sex and race, the incidence proportion was 7.8%
versus 12.3% among white versus black women respectively (p=0.000), and 18.6%
versus 18.8% among white and black men respectively (p=0.900). Figures 6 depict the
incidence proportion of general and cause specific CVD during the 12 years of follow-up
stratified by sex and race.
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Figure 6: General & case specific CVD incidence proportion in ARIC stratified
by sex & race

CVD incidence proportion by sex and race
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b) Mathematical models’ performance
In this section, two mathematical models, namely unadjusted and adjusted
Framingham models, were developed and their mathematical performance compared to
the published (frozen) Framingham model. The unadjusted model was generated by
running a Cox regression model that included only the covariates used to derive the
published Framingham algorithms, while the adjusted model included additional
covariates postulated to improve the discrimination and calibration of the published
Framingham models. The mathematical model performance was evaluated using the
metrics of discrimination and calibration as discussed in the methods section. In addition,
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the regression coefficients generated in the unadjusted model were compared to the
published (frozen) Framingham coefficients to compare the effect size of each covariate
in the Framingham versus ARIC cohorts.
Both the unadjusted and adjusted models met the proportional hazards assumption
(global test >0.05) and did not indicate presence of multicollinearity among the
covariates. To compare the effect of each covariate in the Framingham versus ARIC
cohorts, a statistical test of the difference in their respective regression coefficients (β)
was done using the z-score formula: 𝑧 = (𝑏1 − 𝑏2 )⁄√(𝑠𝑒𝑏12 + 𝑠𝑒𝑏22 ) , where 𝑏1 and
𝑏2 are the unstandardized regression coefficients (β), while 𝑠𝑒𝑏1 and 𝑠𝑒𝑏2 are the standard
errors of the regression coefficients (Paternoster, Brame, Mazerolle, & Piquero, 1998).
Regression coefficients with similar effects across cohorts are expected to have a z score
in the interval -1.96 and +1.96. A positive z means that the regression coefficient in
ARIC was greater than Framingham and vice versa.
The unadjusted non-LB Framingham models
The Cox regression analysis including the non-LB covariates (sex, age, smoking
status, diabetes status, antihypertensive medication use, systolic blood pressure and BMI)
satisfied the proportional hazards assumption with a global test of p=0.2384 among
women and p=0.2873 among men. All the covariates included in the unadjusted non-LB
Framingham model were statistically significant (p<0.05) in both sexes and in the white
cohort, but BMI was not significant in the black cohort (p=0.071 for women and 0.128
for men). In addition, untreated systolic blood pressure was not statistically significant
among black men (p=0.065). Table 4 describes the regression coefficients for the
unadjusted non-LB Framingham model, stratified by sex and race.
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Stratified by sex only, the regression coefficients generated in the unadjusted nonLB Framingham model were similar to the frozen non-LB Framingham regression
coefficients, except for the smoking covariate among men and women, and the diabetes
covariate among men. The effect of smoking was higher among women (z score of 3.28)
but lower among men (z score of -2.842) in ARIC compared to the Framingham cohort.
The effect of diabetes was higher among men (z score of 2.188) but similar among
women in ARIC compared to the Framingham cohort.
Stratified by sex and race, the regression coefficients for all strata were similar to
the frozen non-LB Framingham regression coefficients, except for the smoking and
diabetes coefficients which were different in the white cohort. Smoking had a higher
effect among white women (z score of 3.327) and a lower effect among white men (z score of
-2.637) in ARIC compared to the Framingham cohort. Diabetes had a higher effect among

white men (z score of 2.174) but similar effect among white women in ARIC compared
to the Framingham cohort. Table 4 shows the regression coefficients for the unadjusted
non-LB Framingham model and the associated z scores, stratified by sex and race.
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Table 4: Regression beta coefficients of the unadjusted non-LB Framingham in ARIC
and z test score of equality
Non-LB based
covariates

N
Current smoker
Diabetes
Log of Age
Log of BMI
Log of nontreated SBP

Female coefficients stratified by race

Male coefficients stratified by race

Women

white
women

black
women

Men

white men

black men

6355
1.053***
[0.0885]
z = 3.28†
1.073***
[0.101]
z = 1.65
3.129***
[0.428]
z = 0.788
0.801***
[0.219]
z = 0.828
1.958***
[0.353]
z = -1.701

4758
1.106***
[0.108]
z = 3.327†
1.073***
[0.136]
z = 1.467
3.333***
[0.545]
z = 0.991
0.797**
[0.284]
z = 0.726
1.808***
[0.435]
z = -1.786

1597
0.914***
[0.157]
z =1.592
1.044***
[0.154]
z = 1.25
2.841***
[0.723]
z =0.154
0.668 γ
[0.370]
z = 0.341
2.158***
[0.633]
z = -0.902

5246
0.412***
[0.0707]
z = -2.842†
0.831***
[0.0814]
z = 2.188†
3.050***
[0.321]
z = -0.164
0.793***
[0.222]
z =0.000
1.499***
[0.270]
z = -0.897

4153
0.411***
[0.0826]
z = -2.637†
0.848***
[0.0948]
z = 2.174†
2.881***
[0.372]
z = -0.540
0.864**
[0.265]
z = 0.180
1.790***
[0.323]
z = -0.151

1093
0.501***
[0.145]
z =-1.269
0.831***
[0.161]
z = 1.537
3.330***
[0.654]
z = 0.316
0.631
[0.415]
z = -0.320
1.018γ
[0.551]
z = -1.341

Log of treated
SBP

3.106***
3.054***
3.033***
1.834***
1.719***
[0.389]
[0.600]
[0.531]
[0.399]
[0.497]
z = 0.425
z = 0.247
z = 0.235
z = -0.188
z = -0.361
* p<0.05, ** p<0.01, *** p<0.001 γ p<0.1
Standard errors in brackets
z = score comparing published non-LB Framingham coefficients with those generated in ARIC using the
formulae 𝑓(𝑧) = (𝑏1 − 𝑏2 )⁄√(𝑠𝑒𝑏12 + 𝑠𝑒𝑏22 ); † denotes z score >1.96 or < -1.96. Positive z means the
regression coefficient in ARIC was greater than Framingham & vice versa

In regards to risk stratification and congruence between predicted and observed
CVD events, the unadjusted non-LB Framingham model had a higher discrimination
statistic and better calibration among women compared to men. However, no significant
differences in discrimination were observed between blacks and whites within their
respective sexes. Women had a C statistic of 0.75 (95% confidence interval [CI], 0.730.77) compared to men’s 0.67 (95% CI, 0.65-0.68). When stratified by sex and race,
white women had a C statistic of 0.746 (95% CI, 0.72-0.77) compared to black women’s
0.745 (95% CI, 0.71-0.78), while white men had a C statistic of 0.664 (95% CI, 0.65-
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2.246**
[0.693]
z = 0.425

0.68) compared to black men’s 0.683 (95% CI, 0.65-0.72). The published (frozen) non
LB Framingham model had a C statistic of 0.785 (95% CI, 0.764-0.806) for women and
0.749 (95% CI, 0.731-0.767) for men.
Calibration was good (p>0.05) among women but poor among men with HosmerLemeshow goodness of fit (df 8) χ 2= 14.2 (p=0.1154) versus 25.8 (p=0.0022)
respectively as depicted in Figure 7 and 8 below. When stratified by sex and race,
calibration was good among all ARIC cohorts except white men with Hosmer-Lemeshow
goodness of fit (df 8) χ 2= 19.6 (p=0.0208). The published Framingham model had a
Hosmer-Lemeshow goodness of fit (df 8) χ 2= 10.24 for women (p=0.33) and 13.61
(p=0.14) for men.

Figure 7: Calibration- unadjusted non-LB based Framingham women specific model
Hosmer-Lemeshow goodness of fit : Women (Nlab)
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Figure 8: Calibration- unadjusted non-LB based Framingham men specific model
Hosmer-Lemeshow goodness of fit : Men (Nlab)
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The unadjusted LB Framingham models
The Cox regression analysis including the LB covariates (sex, age, smoking
status, diabetes status, antihypertensive medication use, systolic blood pressure total
cholesterol and HDL) also satisfied the proportional hazards assumption over the
duration of follow-up with a global test of p=0.2999 among women and p=0.4111 among
men. All the covariates included in the unadjusted LB Framingham model were
statistically significant (p<0.05) in both sexes and in the white cohort, but total
cholesterol was not statistically significant in the black cohort (p=0.356 for women and
0.867 for men). Table 5 presents the regression coefficients for the unadjusted LB
Framingham model, stratified by sex and race.
When stratified by sex, all the regression coefficients generated in the unadjusted
LB Framingham model were similar to the frozen LB Framingham regression
54

coefficients, except for the smoking status among men and women. Smoking had a
higher effect among women (z score of 2.946) but a lower effect among men (z score of 2.720) in ARIC compared to the Framingham cohort. Table 5 below describes the
regression coefficients for the unadjusted LB Framingham model and the associated z
scores stratified by sex.
Table 5: Regression beta coefficients of the unadjusted LB Framingham in ARIC and z
test score of equality
LB
covariates

Female coefficients stratified by
race
Women

N
Current
smoker
Diabetes
Log of Age
Log of
T. cholesterol
Log of HDL
Log of nontreated SBP

6355
0.918***
[0.0879]
z= 2.946†
1.004***
[0.0999]
z= 1.745
2.795***
[0.431]
z= 0.884
0.552*
[0.217]
z= -1.923
-0.987***
[0.146]
z= -1.232
2.156***
[0.349]
z= -1.213

white
women
4758

black
women
1597

0.966***
[0.108]

0.780***
[0.155]

0.931***
[0.136]

0.983***
[0.155]

3.121***
[0.551]

2.579***
[0.723]

0.736**
[0.278]

0.320
[0.346]

-1.087***
[0.178]

-0.900***
[0.267]

1.909***
[0.432]

2.273***
[0.633]

Log of
treated SBP

Male coefficients stratified by race

Men

white men

5246

4153

black
men
1093

0.326***
[0.0824]

0.471***
[0.143]

0.803***
[0.0944]

0.803***
[0.159]

2.851***
[0.371]

3.337***
[0.655]

1.254***
[0.202]

0.0581
[0.346]

-0.947***
[0.132]

-0.736**
[0.236]

1.902***
[0.322]

1.270*
[0.555]

0.370***
[0.0700]
z= -2.720†
0.793***
[0.0808]
z= 1.609
2.966***
[0.320]
z= -0.24
0.957***
[0.173]
z= -0.618
-0.896***
[0.112]
z= 0.203
1.793***
[0.273]
z= -0.350

3.209***
2.019***
2.911***
3.065***
1.799***
2.421***
[0.386]
[0.400]
[0.593]
[0.525]
[0.495]
[0.701]
z= 0.741
z= 0.041
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in brackets
z = score comparing published non-LB Framingham coefficients with those generated in ARIC using the
formulae 𝑓(𝑧) = (𝑏1 − 𝑏2 )⁄√(𝑠𝑒𝑏12 + 𝑠𝑒𝑏22 ); † denotes z score >1.96 or < -1.96. Positive z means the
regression coefficient in ARIC was greater than Framingham & vice versa
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The unadjusted LB Framingham model also had a higher discrimination statistic
and better calibration among women compared to men, with no significant differences in
discrimination between blacks and whites within their respective sexes. Women had a C
statistic of 0.76 (95% CI, 0.74-0.78) compared to men’s 0.68 (95% CI, 0.67-0.70). When
stratified by sex and race, white women had a C statistic of 0.754 (95% CI, 0.73-0.78)
compared to black women’s 0.750 (95% CI, 0.72-0.78), while white men had a C statistic
of 0.685 (95% CI, 0.67-0.70) compared to black men’s 0.69 (95% CI, 0.65-0.73). The
published LB Framingham model had a C statistic of 0.793 (95% CI, 0.772-0.814) in
women and 0.763 (95% CI, 0.746-0.780) for men.
Calibration was good (p>0.05) among women but poor among men with
Hosmer-Lemeshow goodness of fit (df 8) χ 2= 10.5 (p=0.3084) versus 21.8 (p=0.0095)
respectively as depicted in Figure 9 and 10. When stratified by sex and race, calibration
was good among all ARIC cohorts except white men with Hosmer-Lemeshow goodness
of fit (df 8) χ 2= 25.5 (p=0.0024). The published LB Framingham model had a HosmerLemeshow goodness of fit (df 8) χ 2= 7.79 for women (p=0.56) and 13.48 (p=0.14) for
men.
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Figure 9: Calibration- unadjusted LB Framingham women specific model
Hosmer-Lemeshow goodness of fit : Women (Lab)
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Figure 10: Calibration- unadjusted LB Framingham men specific model
Hosmer-Lemeshow goodness of fit : Men (Lab)
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The adjusted non-LB model
In a bid to improve discrimination and calibration, additional variables known to
be CVD risk factors were sequentially added to the covariates included in the published
non-LB Framingham model, and their statistical significance evaluated. The additional
variables included waist hip ratio and family history of premature CHD. A new model
(adjusted non-LB model) including covariates that were statistically significant in
multivariate regression was generated and its performance evaluated through the metrics
of discrimination and calibration.
Family history of premature CHD was statistically significant among men, but not
among women (p=0.068). Waist hip ratio was marginally significant among women
(p=0.052), but the addition of waist hip ratio rendered BMI no longer significant (0.946)
among men. Table 6 describes each covariate’s regression coefficient and the
corresponding standard error and p value.
When stratified by sex and race, BMI was significant among white women but
statistically not significant among white men (p=0.34), black women (p=0.445) and black
men (p=0.535). On the other hand, waist hip ratio was significant among blacks and
white men, but statistically not significant among white women (p=0.338). Family
history of premature CHD was statistically not significant among white women
(p=0.127), black women (p=0.195) and black men (p=0.971), but significant among
white men. In addition, untreated systolic blood pressure was not statistically significant
among black men (p=0.101). Table 6 describes the regression coefficients for the
adjusted non-LB model, stratified by sex and race.
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Table 6: Regression coefficients of the adjusted non-LB model stratified by sex and race
Adjusted non-LB
model covariates

Female coefficients stratified by race

Male coefficients stratified by race

women

white women

black women

men

white men

black men

6353

4758

1597

4406

3612

1093

1.023***
[0.0895]

1.106***
[0.108]

0.830***
[0.154]

0.373***
[0.0771]

0.365***
[0.0882]

0.475***
[0.142]

Diabetes

1.028***
[0.103]

1.073***
[0.136]

0.982***
[0.156]

0.844***
[0.0897]

0.881***
[0.101]

0.773***
[0.161]

Log of Age

2.947***
[0.441]

3.333***
[0.545]

2.433***
[0.723]

2.772***
[0.354]

2.706***
[0.398]

2.997***
[0.658]

Log of BMI

0.597*
[0.242]

0.797**
[0.284]

N/A

N/A

N/A

N/A

Log of waist hip
ratio

1.141
[0.587]

N/A

2.462**
[0.906]

3.631***
[0.660]

3.799***
[0.757]

3.848**
[1.229]

N/A

N/A

N/A

0.334**
[0.109]

0.359**
[0.114]

N/A

1.906***
[0.355]

1.808***
[0.435]

2.071**
[0.635]

1.500***
[0.297]

1.641***
[0.350]

0.909
[0.554]

3.097***
[0.390]

3.054***
[0.600]

3.092***
[0.531]

1.800***
[0.434]

1.803***
[0.519]

2.196**
[0.698]

N
Current smoker

Family hx of
premature CHD
Log of non-treated
SBP
Log of treated SBP

Standard errors in brackets, N/A= not applicable
* p<0.05, ** p<0.01, *** p<0.001, γ p≤0.1

There was no difference in discrimination between the adjusted and unadjusted
non-LB models. Women maintained a C statistic of 0.75 (95% CI, 0.73-0.77) compared
to men’s 0.67 (95% CI, 0.66-0.69). When stratified by sex and race, there was no
significant difference in discrimination. white women had a C statistic of 0.746 (95% CI,
0.72-0.77) compared to black women’s 0.748 (95% CI, 0.71-0.78), while white men had
a C statistic of 0.675 (95% CI, 0.65-0.69) compared to black men’s 0.689 (95% CI, 0.650.72).
There was minimal improvement in calibration with women still maintaining
good calibration compared to men with Hosmer-Lemeshow goodness of fit (df 8) χ 2=
12.4 (p=0.189) versus 21.2 (p=0.0115) respectively. When stratified by sex and race,
calibration was good in all groups stratified by sex and race.
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The adjusted LB model
To improve the LB Framingham model, variables that included BMI, waist hip
ratio, family history of premature CHD, apolipoprotein A and apolipoprotein B were
added to the model. A new model (adjusted LB model) including covariates that were
statistically significant in multivariate regression was generated and its performance
evaluated through the metrics of discrimination and calibration.
Total cholesterol, waist hip ratio and family history of premature CHD were
statistically significant in predicting CVD events among men, but not among women (p=
0.765 and 0.327 and 0.106 respectively). On the other hand, apolipoprotein B was
significant among women but not among men (p=0.969) as shown in Table 7. BMI and
apolipoprotein A were not significant among women (p= 0.592 and 0.585 respectively) or
men (p= 0.288 and 0.938 respectively). All other variables were significant in both sexes
as described in Table 7.
When stratified by sex and race, apolipoprotein B was significant among white
women but not significant among black women (p=0.238), white men (p=0.953) and
black men (p=0.853), waist hip ratio was significant among blacks and white men, but
statistically not significant among white women (p=0.897). Family history of premature
CHD was statistically not significant among white women (p=0.148), black women
(p=0.224) and black men (p=0.955), but was significant among white men. In addition,
untreated systolic blood pressure was marginally significant among black men (p=0.055).
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Table 7: Regression coefficients of the adjusted LB model stratified by race and sex
Adjusted LB
model covariates

Female coefficients stratified by race

Male coefficients stratified by race

women
0.916***
[0.0880]

white women
0.960***
[0.108]

black women
0.771**
[0.155]

men
0.368***
[0.0773]

white men
0.332***
[0.0890]

black men
0.475***
[0.142]

Diabetes

1.002***
[0.100]

0.935***
[0.136]

0.910***
[0.158]

0.787***
[0.0903]

0.806***
[0.102]

0.740***
[0.161]

Log of Age

2.809***
[0.429]

3.164***
[0.548]

2.482***
[0.722]

2.878***
[0.356]

2.814***
[0.399]

3.125***
[0.664]

N/A

N/A

N/A

0.812***
[0.192]

1.043***
[0.217]

N/A

-0.877***
[0.151]

-0.955***
[0.185]

-0.770**
[0.271]

-0.800***
[0.131]

-0.847***
[0.149]

-0.561*
[0.244]

0.368**
[0.141]

0.490**
[0.183]

N/A

N/A

N/A

N/A

N/A

N/A

1.980*
[0.922]

2.360***
[0.706]

2.723***
[0.800]

2.958*
[1.297]

N/A

N/A

N/A

0.297**
[0.109]

0.322**
[0.114]

N/A

2.154***
[0.349]

1.893***
[0.432]

2.119***
[0.641]

1.670***
[0.303]

1.628***
[0.353]

1.076
[0.561]

3.181***
[0.387]
6352

2.794***
[0.597]
4757

3.019***
[0.525]
1597

1.920***
[0.437]
4406

1.838***
[0.519]
3612

2.301**
[0.705]
1093

Current smoker

Log of total
cholesterol
Log of HDL
Log of ApoB
Log of waist hip
ratio
Family hx of
premature CHD
Log of nontreated SBP
Log of treated
SBP
N

Standard errors in brackets, N/A= not applicable
* p<0.05, ** p<0.01, *** p<0.001, γ p<0.1

There was no difference in discrimination between the adjusted and unadjusted
LB models. Women had a C statistic of 0.76 (95% CI, 0.74-0.78) compared to men’s
0.69 (95% CI, 0.67-0.71). When stratified by sex and race, there was no significant
difference in discrimination. white women had a C statistic of 0.755 (95% CI, 0.73-0.78)
compared to black women’s 0.753 (95% CI, 0.72-0.79), while white men had a C statistic
of 0.693 (95% CI, 0.67-0.71) compared to black men’s 0.693 (95% CI, 0.66-0.73).
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Both sexes had similar calibration with Hosmer-Lemeshow goodness of fit (df 8)
χ 2= 18.6 among women (p=0.0289) versus 18.1 (p=0.0343) among men. When stratified
by sex and race, calibration was good in all groups except among white men with
Hosmer-Lemeshow goodness of fit (df 8) χ 2= 20.3 (p=0.0164).
c) Applicability of the Framingham algorithms in the ARIC sample
In this section, the published (frozen) non-LB and LB Framingham algorithms are
imputed in the ARIC dataset and applied to stratify CVD risk in the ARIC sample. In
addition, two more risk prediction functions (recalibrated Framingham and adjusted
algorithms) are derived using ARIC dataset, and their performance in stratifying CVD
risk compared to the frozen Framingham algorithms using kappa statistic and
sensitivity/specificity analysis. The three CVD risk prediction algorithms adhere to the
general formulae outlined in the literature review section [ 𝑝̃ = 1 −
𝑝

̇

𝑝

̇

S0 (𝑡)exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−∑𝑖 =1 𝛽𝑖𝑋̅𝑖) ] which is widely used in Framingham and other studies to
generate CVD risk prediction algorithms.
The frozen Framingham algorithms simply adopt all features of the published
Framingham risk prediction functions, while the recalibrated algorithms alter the
published Framingham functions by substituting their baseline survival and mean of risk
factors with ARIC generated baseline survival and mean of risk factors. The adjusted
algorithms alter the published Framingham risk function by substituting their baseline
survival, covariates and regression coefficients with those generated in ARIC.
CVD risk stratification using the frozen Framingham algorithms
The frozen non-LB Framingham algorithm calculates the 10-year CVD risk for
𝑝

̇

women as 𝑝̃ = 1 − 0.94833exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−26.0145) ; while the risk for men is calculated as
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𝑝

̇

𝑝̃ = 1 − 0.88431exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−23.9388) . On the other hand, the frozen LB Framingham
𝑝

̇

algorithm calculates the risk for women as 𝑝̃ = 1 − 0.95012 exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−26.1931) , and
𝑝

̇

the risk for men as 𝑝̃ = 1 − 0.88936 exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−23.9802) . In addition to using the
Framingham’s baseline survival and mean of risk factors, the frozen Framingham
algorithms also use the Framingham generated regression coefficients (𝛽̇ 𝑖) in the
equations above.
When the frozen Framingham algorithms were applied to stratify CVD risk in the
entire ARIC sample, the outcome was comparable in all risk categories. For instance, the
non-LB Framingham algorithm classified 18% of the sample as high or very high risk
(see Figure 11 below) compared to 17% by the frozen LB Framingham algorithm (Figure
12 below). When the four risk categories stratified by the two frozen Framingham
algorithms were compared by kappa test, there was an overall agreement of 92.76% and a
kappa statistic of 0.7624 as described in Table 8 below.
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Figure 11: Risk stratification in ARIC cohort as per the Frozen non-LB Framingham

Frozen non-lab based Framingham algorithm
Entire ARIC cohort, 4 risk strata
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Figure 12: Risk stratification in ARIC cohort as per the Frozen LB Framingham

Frozen lab based Framingham algorithm
Entire ARIC cohort, 4 risk strata

7%
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very high

Source: ARIC dataset)

64

Table 8: Kappa test frozen non-LB versus LB Framingham algorithm’s risk categories
Frozen non-LB
Frozen LB Framingham algorithm
based
Framingham
low
moderate high
very Total
algorithm
5,696
809
9
0
6,514
low
high
392
2,241
443
31
3,107
moderate
3
350
642
198
1,193
high
0
16
208
563
787
very high
6,091
3,416
1,302
792
11,601
total
Ratings weighted by:
1.0000
0.6667
0.3333
0.0000

0.6667
1.0000
0.6667
0.3333

0.3333
0.6667
1.0000
0.6667

Agreement Expected
Agreement
92.76%
69.56%

0.0000
0.3333
0.6667
1.0000

Kappa

Std. Err.

Z

Prob>Z

0.7624

0.0069

111.28

0.0000

When the frozen non-LB Framingham algorithm was used to classify CVD risk in
the ARIC sample stratified by sex and race, a greater proportion of black women and
black men were classified as high or very high risk compared to their white counterparts.
The proportion of black women in the high risk category was 4.3% more than the
proportion of white women (7.8% versus 3.5% respectively), while the proportion of
black women in the very high risk category was 4.4% more than the proportion of white
women (5.9% versus 1.5% respectively) as depicted in Figure 13 below.
Among men, blacks dominated the high and very high risk categories. The
proportion of black men in the high risk category was 6.2% higher compared to white
men (24.2% versus 18.0% respectively). In the very high risk category, the proportion of
black men was 10% higher than the proportion of white men (19.9% versus 9.9%
respectively) as described in Figure 13.
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Figure 13: Frozen non-LB Framingham algorithm risk categories stratified by sex & race
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Data source: ARIC 1987-1999

When the frozen LB Framingham algorithm was applied to classify CVD risk in
the ARIC sample stratified by sex and race, higher proportions of blacks dominated the
high and very high risk categories compared to whites. The proportion of black women in
the high risk category was 3.5% higher than the proportion of white women (6.8% versus
3.3% respectively), while the proportion of black women in the very high risk category
was 2.8% higher than the proportion of white women (4.4% versus 1.6% respectively) as
depicted in Figure 14 below. Among men, the differences in the high and very high risk
categories were minimal, with 20.1% of black men and 17.1% of white men being
classified as high risk (3% difference), and 15% of black men versus 11.4% of white men
classified in the very high risk category (3.6% difference) as depicted in Figure 14.
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Figure 14: Frozen LB Framingham algorithm risk categories stratified by sex & race
Frozen LB Framingham risk categories stratified by sex and race
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CVD risk stratification using the recalibrated Framingham algorithms
Recalibration of the Framingham algorithms was done by replacing their baseline
survival and mean of risk factors with values generated in the ARIC sample, but the
Framingham generated regression coefficients (𝛽̇ 𝑖) were retained. In the ARIC sample,
the baseline survival adjusted for the non-LB covariates was 0. 9111038 for women and
0.8335824 for men. The baseline survival adjusted for the LB covariates was
0.9033732 and 0.8461685 for women and men respectively in the ARIC sample.
Therefore, the recalibrated non-LB algorithm calculates the 10-year CVD risk for
𝑝

̇

women as 𝑝̃ = 1 − 0. 9111038exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−27.127605) ; while the risk for men is
𝑝

̇

calculated as 𝑝̃ = 1 − 0.8335824exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−24.78308) . On the other hand, the
recalibrated LB algorithm calculates the risk for women as 𝑝̃ = 1 −
𝑝

̇

0.9033732 exp (𝐴 ∑𝑖 =1 𝛽𝑖𝑋𝑖−27.18902) , and the risk for men as 𝑝̃ = 1 −
𝑝

̇

0.8461685 exp(∑𝑖 =1 𝛽𝑖𝑋𝑖−24.780015) .
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When the recalibrated algorithms were applied to stratify CVD risk in the entire
ARIC sample, the outcome was comparable in all risk categories. For instance, the
recalibrated non-LB algorithm classified 7.44% of the sample as high or very high risk
compared to 8.09% by the recalibrated LB algorithm. When the four risk categories
stratified by the two recalibrated algorithms were compared by kappa test, there was an
overall agreement of 94.26% and a kappa statistic of 0.72.
When the recalibrated algorithms were applied to classify CVD risk in the ARIC
sample stratified by sex and race, there was no difference between the non-LB and LB
algorithm, or between blacks and whites. However, higher proportions of men were
classified in the high and very high risk strata compared to women in both racial groups
by both algorithms as described in Figures 15 and 16.

Figure 15: Recalibrated non-LB algorithm risk categories stratified by sex & race
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Figure 16: Recalibrated LB algorithm risk categories stratified by sex & race
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CVD risk stratification using the adjusted algorithms
The adjusted algorithms were generated by replacing the baseline survival, mean
of risk and regression coefficients of the general CVD formulae with values generated in
the ARIC sample. In the ARIC sample, the baseline survival adjusted for the additional
non-LB covariates (described in the mathematical performance section) was 0. 908755
for women and 0.8518082 for men. The baseline survival for the adjusted LB covariates
was 0.9032351 and 0.8568301 for women and men respectively in the ARIC sample.
Therefore, the adjusted non-LB algorithm calculates the 10-year CVD risk for
𝑝

̇

women as 𝑝̃ = 1 − 0.908755 exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−26.73064) ; while the risk for men is calculated
𝑝

̇

as 𝑝̃ = 1 − 0.8518082exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−21.26414) . On the other hand, the adjusted LB
𝑝

̇

algorithm calculates the risk for women as 𝑝̃ = 1 − 0.9032351 exp (∑𝑖 =1 𝛽𝑖𝑋𝑖−27.747355) ,
and the risk for men as 𝑝̃ = 1 − 0.8568301

𝑝
exp (∑𝑖 =1 𝛽̇𝑖𝑋𝑖−23.347965)
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When the adjusted algorithms were applied to stratify CVD risk in the entire
ARIC sample, there was no difference between categories. For instance, the adjusted
non-LB algorithm classified 6.88% of the sample as high or very high risk compared to
5.90% by the adjusted LB algorithm. When the four risk categories stratified by the two
algorithms were compared by kappa test, there was an overall agreement of 96.12% and a
kappa statistic of 0.7996.
When the adjusted algorithms were applied to classify CVD risk in the ARIC
sample stratified by sex and race, there was no difference between the non-LB and LB
algorithm, or between blacks and whites. However, higher proportions of men were
classified in the high and very high risk strata compared to women in both racial groups
by both algorithms as described in Figures 17 and 18.
Figure 17: Adjusted non-LB algorithm risk categories stratified by sex & race
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Figure 18: Adjusted LB algorithm risk categories stratified by sex & race
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d) Sensitivity/specificity analysis
Sensitivity/specificity analysis was done to determine the clinical usefulness of
the non-LB and LB versions of the three algorithms described above. Sensitivity of
each algorithm was determined by the proportion of the sample with incident CVD
who are correctly identified as high risk by the algorithm. Specificity was dictated by
the proportion of the sample without incident CVD who were classified as low risk by
the algorithm. The roctab command in Stata© was used to calculate and plot the
nonparametric AUROC based on sensitivity/specificity analysis for each algorithm.
Sensitivity/specificity analysis of the frozen Framingham algorithms
Although the Framingham algorithms are ideally intended to predict CVD risk
within a time frame of 10 years, they can be extended to a maximum of a 12 years as
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discussed in the methods section. Therefore, the analysis described in this section
focuses on their sensitivity/specificity analysis within 12 years’ time frame.
The frozen non-LB Framingham algorithm
In the entire ARIC sample, the frozen non-LB Framingham algorithm had an
overall AUROC of 0.7063. At the moderate risk category (10-20%), the algorithm had a
sensitivity of 76% and specificity of 57.03%. When the high risk (20-30%) cut point was
used as the threshold for predicted incident CVD, the algorithm had a sensitivity of
41.10% versus specificity of 85.49%. Table 9 below describes a detailed report of the
algorithm’s sensitivity and specificity at the four different risk cut points described in the
methods section, while Figure 19 plots the resultant AUROC.
Table 9: Sensitivity/specificity analysis of the frozen non-LB Framingham algorithm
Any CVD event within first
12yrs of follow-up

Frozen non-LB based Framingham risk categories in ARIC

low
moderate
high
5,735
2,862
965
CVD free
356
554
337
Incident CVD
6,091
3,416
1,302
Total
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
Correctly
Classified
100.00%
0.00%
13.32%
>=low risk (<10%)
76.96%
57.03%
59.68%
>=moderate risk (10-20%)
41.10%
85.49%
79.58%
>=high risk (20-30%)
19.29%
95.09%
84.99%
>=very high risk (>30% )
0.00%
100.00%
86.68%
> very high risk

very high
494
298
792
LR+
1.0000
1.7910
2.8328
3.9263
1.0000

ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------11,601 0.7063
0.0068
0.69294 0.71969
Sensitivity= fraction of true positive cases
Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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Total
10,056
1,545
11,601
LR-
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Figure 19: Frozen non-LB Framingham AUROC for entire ARIC sample
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When the ARIC sample was stratified by sex and race, the algorithm’s AUROCs
for women and blacks were higher compared to men and whites respectively. Figures 2023 plots the frozen non-LB based Framingham AUROCs stratified by sex and race.
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Figure 21: Frozen non-LB Framingham AUROC
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Figure 20: Frozen non-LB Framingham AUROC
white women
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Figure 23: Frozen non-LB Framingham AUROC
black men
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Figure 22: Frozen non-LB Framingham AUROC
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The frozen LB Framingham algorithm
In the entire ARIC sample, the frozen LB Framingham algorithm had an overall
AUROC of 0.71. At the moderate risk (10-20%) threshold, the algorithm had a sensitivity
of 74.63% and specificity of 60.88%. When the high risk (20-30%) cut point is used as
the threshold for predicted incident CVD, the algorithm had a sensitivity of 40.32%
versus specificity of 86.51%. Table 10 below describes a detailed report of the
algorithm’s sensitivity and specificity at the four different risk cut points described in the
methods section, while Figure 24 plots the resultant AUROC. Both frozen Framingham
algorithms (non-LB and LB) had similar AUROCs with no statistical difference in their
sensitivity and specificity (p=0.3661) as depicted in Figure 25.
Table 10: Sensitivity/specificity analysis of the frozen LB Framingham algorithm
Any CVD event within first
12yrs of follow-up

Frozen LB based Framingham risk categories in ARIC

low
moderate
high
6,122
2,577
880
CVD free
392
530
313
Incident CVD
6,514
3,107
1,193
Total
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
Correctly
Classified
100.00%
0.00%
13.32%
>=low risk (<10%)
74.63%
60.88%
62.71%
>=moderate risk (10-20%)
40.32%
86.51%
80.36%
>=high risk (20-30%)
20.06%
95.26%
85.24%
>=very high risk (>30% )
0.00%
100.00%
86.68%
> very high risk

very high
477
310
787
LR+
1.0000
1.9076
2.9882
4.2300

ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------11,601 0.7100 0.0068
0.69661 0.72345
Sensitivity= fraction of true positive cases
Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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Figure 24: Frozen LB Framingham AUROC for entire ARIC sample
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Figure 25: Comparing frozen Framingham algorithms’ AUROCs in entire ARIC sample
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When the ARIC sample was stratified by sex and race, the frozen LB
Framingham algorithm’s AUROCs for blacks were higher compared to whites. Figures
26-28 plots these AUROCs stratified by sex and race.
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Figure 27: Frozen LB Framingham AUROC
black women
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Figure 26: Frozen LB Framingham AUROC
white women
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Figure 29: Frozen LB Framingham AUROC
black men
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Figure 28: Frozen LB Framingham AUROC
white men
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Sensitivity/specificity analysis of the recalibrated algorithms
The recalibrated non-LB algorithm
In the entire ARIC sample, the recalibrated non-LB algorithm had an overall ROC
of 0.6711. At the moderate risk category (10-20%), the algorithm had a sensitivity of
58.58% and specificity of 73.45%. When the high risk (20-30%) cut point was used as
the threshold for predicted incident CVD, the algorithm had a sensitivity of 20.13%
versus specificity of 94.51%. Table 11 below describes a detailed report of the
algorithm’s sensitivity and specificity at the four different risk cut points, while Figure 30
plots the resultant AUROC.
Applied to the ARIC sample stratified by sex and race, the recalibrated algorithm
had the highest AUROC for black women (0.6691) followed by black men (0.6577).
white men had a higher AUROC (0.6383) compared to white women (0.5890).
Table 11: Sensitivity/specificity analysis of the recalibrated non-LB algorithm
Any CVD event within first
12yrs of follow-up

Recalibrated non-LB algorithm risk categories in ARIC

low
moderate
high
CVD free
7,386
2,118
431
Incident CVD
640
594
226
Total
8,026
2,712
657
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
Correctly
Classified
>=low risk (<10%)
100.00%
0.00%
13.32%
>=moderate risk (10-20%)
58.58%
73.45%
71.47%
>=high risk (20-30%)
20.13%
94.51%
84.60%
>=very high risk (>30% )
5.50%
98.80%
86.37%
> very high risk
0.00%
100.00%
86.68%
ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------11,601 0.6711
0.0069
0.65745 0.68469
Sensitivity= fraction of true positive cases
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very high
121
85
206
LR+
1.0000
2.2061
3.6671
4.5723

Total
10,056
1,545
11,601
LR-

0.5640
0.8451
0.9565
1.0000

Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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Figure 30: Recalibrated non-LB Framingham AUROC for entire ARIC sample
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The recalibrated LB algorithm
In the entire ARIC sample, the recalibrated LB algorithm had an overall AUROC
of 0.6851. At the moderate risk category (10-20%), the algorithm had a sensitivity of
60.84% and specificity of 73.73%. When the high risk (20-30%) cut point was used as the

threshold for predicted incident CVD, the algorithm had a sensitivity of 22.46% versus
specificity of 94.12%. Table 12 below describes a detailed report of the algorithm’s
sensitivity and specificity at the four different risk cut points, while Figure 31 plots the
resultant AUROC.
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Applied to the ARIC sample stratified by sex and race, the recalibrated LB
algorithm had similar AUROC for black men (0.6648) and white men AUROC (0.6644).
black women had a higher AUROC (0.6622) compared to white women (0.6230).

Table 12: Sensitivity/specificity analysis of the recalibrated LB algorithm
Any CVD event within first
12yrs of follow-up

Recalibrated LB risk categories in ARIC

low
moderate
high
7,414
2,051
444
CVD free
605
593
226
Incident CVD
8,019
2,644
670
Total
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
Correctly
Classified
100.00%
0.00%
13.32%
>=low risk (<10%)
60.84%
73.73%
72.01%
>=moderate risk (10-20%)
22.46%
94.12%
84.58%
>=high risk (20-30%)
7.83%
98.54%
86.46%
>=very high risk (>30% )
0.00%
100.00%
86.68%
> very high risk

very high
147
121
268
LR+
1.0000
2.3158
3.8215
5.3575

ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------11,601 0.6851
0.0069
0.67158 0.69868
Sensitivity= fraction of true positive cases
Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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Figure 31: Recalibrated LB Framingham AUROC for entire ARIC Cohort
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Total
10,056
1,545
11,601
LR-

0.5311
0.8238
0.9354
1.0000

Sensitivity/specificity analysis of the adjusted algorithms
The adjusted non-LB algorithm
In the entire ARIC sample, the adjusted non-LB algorithm had an overall
AUROC of 0.6768. At the moderate risk category (10-20%), the algorithm had a
sensitivity of 56.77% and specificity 76.20%. When the high risk (20-30%) cut point was
used as the threshold for predicted incident CVD, the algorithm had a sensitivity of
21.02% versus specificity of 95.23%. Table 13 below describes a detailed report of the
algorithm’s sensitivity and specificity at the four different risk cut points, while Figure 32
plots the resultant AUROC.
When applied to the ARIC sample stratified by sex and race, the adjusted non-LB
algorithm had the highest AUROC in black women (0.6793), while white women had the
lowest AUROC (0.6066). White men had similar AUROC (0.6568) with black men
(0.6580).
Table 13: Sensitivity/specificity analysis of the adjusted non-LB algorithm
Any CVD event within first
12yrs of follow-up

Adjusted non-LB categories in ARIC

low
CVD free
6,470
Incident CVD
549
Total
7,019
Detailed report of sensitivity and specificity
Cut point
Sensitivity

moderate
1,616
454
2,070
Specificity

high
271
151
422

very high
134
116
250

Correctly
LR+
Classified
>=low risk (<10%)
100.00%
0.00%
13.01%
1.0000
>=moderate risk (10-20%)
56.77%
76.20%
73.67%
2.3852
>=high risk (20-30%)
21.02%
95.23%
85.58%
4.4077
>=very high risk (>30% )
9.13%
98.42%
86.80%
5.7877
> very high risk
0.00%
100.00%
86.99%
ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------9,761 0.6768
0.0077
0.66183 0.69187
Sensitivity= fraction of true positive cases; Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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Figure 32: Adjusted non-LB algorithm AUROC for entire ARIC sample
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The adjusted LB algorithm
In the entire ARIC sample, the adjusted LB algorithm had an overall AUROC of
0.6908. At the moderate risk category (10-20%), the algorithm had a sensitivity of

58.98% and specificity of 76.73%. When the high risk (20-30%) cut point was used as the
threshold for predicted incident CVD, the algorithm had a sensitivity of 22.05% versus
specificity of 95.24%. Table 14 below describes a detailed report of the algorithm’s
sensitivity and specificity at the four different risk cut points, while Figure 33 plots the
resultant AUROC.
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Applied to the ARIC sample stratified by sex and race, the adjusted LB algorithm
had the highest AUROC for black women (0.7033) followed by white men (0.6783).
black men had a higher AUROC (0.6411) compared to white women (0.6317).
Table 14: Sensitivity/specificity analysis of the adjusted LB algorithm
Any CVD event within first
12yrs of follow-up

Adjusted LB categories in ARIC

low
moderate
CVD free
6,515
1,572
Incident CVD
521
469
Total
7,036
2,041
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
>=low risk (<10%)
>=moderate risk (10-20%)
>=high risk (20-30%)
>=very high risk (>30% )
> very high risk

high
288
163
451

very high
116
117
233

Correctly
LR+
Classified
100.00%
0.00%
13.01%
1.0000
58.98%
76.73%
74.42%
2.5343
22.05%
95.24%
85.72%
4.6337
9.21%
98.63%
87.00%
6.7435
0.00%
100.00%
86.99%
ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------9,761 0.6908
0.0076
0.67592 0.70574

Sensitivity= fraction of true positive cases; Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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Figure 33: Adjusted LB algorithm AUROC for entire ARIC sample
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1.00

Total
8,491
1,270
9,761
LR-

0.5347
0.8185
0.9204
1.0000

Comparing sensitivity/specificity of all algorithms
When all non-LB algorithms (frozen, recalibrated and adjusted) were compared in
the entire ARIC sample, the frozen non-LB Framingham had the highest AUROC
(0.7086), while the recalibrated model had the lowest (0.6697) as described in Figure 34
below. Among the LB algorithms, the frozen non-LB algorithm had the highest AUROC
(0.7141) while the recalibrated algorithm had the lowest (0.6868) as depicted in Figure
35 below.
When the frozen LB Framingham algorithm was compared to all non-LB
algorithms in the entire ARIC sample, the frozen LB Framingham had the highest
AUROC (0.7141) followed by the frozen non-LB Framingham (0.7086). The recalibrated
non-LB model had the lowest AUROC (0.6697) as described in Figures 36 and 37.
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Figure 35: Comparing all LB algorithms
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Figure 34: Comparing all non-LB algorithms
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Figure 37: Comparing frozen non-LB
with all LB algorithms
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Figure 36: Comparing frozen LB with all
non-LB algorithms
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e) Simulated cost-effectiveness analysis of the non-LB Framingham algorithm
Introduction
To determine the cost-effectiveness of the non-LB Framingham algorithm, the
expenses and outcomes associated with the three simulated CVD prevention programs
described in the methods were calculated. The expenses were costed at three levels which
are consistent with the steps inherent in CVD prevention programs. Level I expenses are
the screening costs and are determined by the unit cost of screening an individual in each
program. Level II expenses are the costs of preventive interventions prescribed in each
program and are driven by the number of true and false positive cases associated with
each program. Level III expenses includes the downstream costs of treating false negative
cases associated with each preventive program. The outcomes describing the
effectiveness of each program were quantified by identifying the true positive cases
associated with each preventive program.
The costs and outcomes associated with each program were used to compute their
respective average cost-effectiveness ratios. Finally, incremental cost-effectiveness
analysis was done where existing programs (status quo) were considered to be the
individual risk factors and LB absolute risk approaches to CVD prevention, while the
new program was considered to be the non-LB absolute risk approach.
Level I: Expenses in screening for CVD
Level I expenses are the over-time, non-recurring marginal costs incurred during a
patient’s first routine office visit when the provider screens a patient to assess CVD risk.
These expenses include the extra Registered Nurses (RN) hours spent taking a patient’s
medical history and obtaining physiological measures to appraise CVD risk. The office
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visit itself is not costed because the cost is incurred regardless of whether CVD screening
takes place or not.
It has been estimated that an individual’s absolute risk score can be calculated
within ten minutes using non-LB algorithms because the only data required include: sex,
age, smoking status, diabetes status, antihypertensive medication use, systolic blood
pressure and BMI (D'Agostino RB et al., 2008; Gaziano et al., 2008). For purposes of this
study, the RN time required to appraise CVD risk based on individual risk factors
(diabetes and/or hypertension) was estimated to be 5 minutes because only the
demographic and relevant history/physiologic data are collected without calculating any
risk scores. The RN screening time using the LB Framingham algorithm was assumed to
be similar to the non-LB algorithm since the extra time for assessing lipids was costed
under the laboratory expenses.
The basic equipment needed for either preventive approach (i.e. weighing scale,
tape measure, glucometer and sphygmomanometer) are readily available in most primary
care offices; hence no additional capital inputs are required for screening. The diagnostic
cost of blood glucose testing for diabetes is required for the three CVD prevention
programs. The LB absolute risk approach has additional diagnostic costs for HDL and
total cholesterol tests. The absolute CVD risk score can be calculated for both approaches
by an interactive online calculator or an offline calculator embedded in a downloadable
excel spread sheet. Alternatively, the absolute CVD risk scores can be calculated
manually by a paper based tool that aggregates points associated with each covariate
included in the Framingham algorithms. Both the online and offline calculators, and the
paper tool can be accessed for free at the Framingham heart study website. This analysis
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assumed use of the offline calculators, because of their efficiency and applicability to
settings without internet connection.
All costs were based on Mississippi payment rates because most of the black
participants in ARIC were recruited from Jackson, Mississippi (ARIC Investigators,
1989). The RN hourly wage is based on Bureau of Labor Statistics median RN hourly
wage for the state of Mississippi which is $27.19/hr. (Bureau of Labor Statistics, 2014).
Since the Centers for Medicare and Medicaid (CMS) have well established
reimbursement rates for diagnostic tests, screening for diabetes and lipids were costed
based on the 2016 clinical diagnostic laboratory fee schedule in Mississippi.
Reimbursement for diabetes was calculated using Current Procedure Terminology (CPT
code 82962 ($3.19) while HDL and total cholesterol tests were costed under CPT codes
83718 ($11.16) and 82465 ($5.92) respectively (Centers for Medicare & Medicaid
Services, 2015a). Medicare rates were assumed close to true marginal costs because
many tests are conducted at these rates which are lower than with private insurance.
The screening costs are calculated for each CVD prevention strategy in equations
1a-c and summarized in Table 15. Both approaches will incur costs for screening the
2,690 eligible black sample in the ARIC dataset.
Equation 1a: The individual CVD risk factors (DM/HTN) approach:
Screenr = 2690 individuals ∗ [(5min ∗ $0.45) + $3.19] = $14,634
Equation 1b: The non-LB absolute CVD risk approach:
Screena = 2690 individuals ∗ [(10min ∗ $0.45) + $3.19] = $20,686
Equation 1c: The LB absolute CVD risk approach:
Screenl = 2690 individuals ∗ [(10min ∗ $0.45) + $3.19 + $11.16 + $5.92 = $66,631
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Table 15: Marginal screening costs: individual risk factors vs absolute non-LB vs LB
absolute risk approach
Costed screening items

Individual risk factors
(DM/HTN)
5 mins

Absolute CVD risk
(non-LB Framingham )
10 mins

Absolute CVD risk
(LB Framingham )
10 mins

$0.45/min

$0.45/min

$0.45/min

$3.19

$3.19

$3.19

HDL test

$0

$0

$11.16

Total cholesterol test

$0

$0

$5.92

$5.44

$7.69

$24.77

$14,634

$20,686.1

$66,631.3

RN screening min/person
RN hourly wage ($27.19/hr.)
Fasting glucose test cost

Total Screening costs/person
Total Screening costs

Screening time is estimated as suggested by Gaziano et al. (2008)
RN wages are the 2014 average RN wages for Mississippi reported by Bureau of Labor Statistics.
Fasting glucose, HDL and total cholesterol test costs are based on reimbursement for CPT codes 82962, 83718 and
82465 respectively in Mississippi

Level II: Expenses of initial and follow-up visits for positive cases
If a patient is determined to be at risk for CVD, guidelines recommend a battery
of follow-up steps. Initial and follow-up office visits are costed using the Medicare
physician fee schedule. The drugs prescribed by each CVD prevention approach (see
Figure 3 and Table 2) are identified by their National Drug Code (NDC), and costed
using the National Average Drug Acquisition Cost (NADAC) compiled by Medicaid in
the last week of December 2015 (Centers for Medicare & Medicaid Services, 2015c;
Medicaid.gov, 2016).
Level II expenses are influenced by the number of participants classified above a
certain risk threshold and the cost of interventions prescribed by each CVD preventive
strategy (see Table 2 for absolute CVD risk programs and Figure 3 for individual risk
factors program). A CVD preventive strategy with many false positives unnecessarily
increases level II expenses with fewer prevented CVD events.
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The moderate risk category (absolute CVD risk score ≥10) was selected as the
optimal risk threshold for the absolute CVD risk programs and the high risk category
(presence of diabetes and/or hypertension) for the individual CVD risk factor program.
These thresholds were based on sensitivity/specificity analyses outlined in Table 16 (for
the individual CVD risk factors program) and Table 17 and 18 (for the absolute CVD risk
programs).
When the high risk category was applied as the treatment threshold in the
approach based on treating individual CVD risk factors, there were 1045 true negatives
and 88 false negatives, along with 313 true positives and 1244 false positives as detailed
in Table 16. The false and true negatives (1133 cases) were not be prescribed the
preventive treatments outlined in Figure 3, and did not contribute to level II expenses. On
the other hand, the false and true positives (1557) received the preventive interventions
and contributed to level II expenses.
Table 16: Sensitivity/specificity analysis of the individual risk factors strategy
Any CVD event within first 12yrs
of follow-up

Individual risk factors (DM/HTN) risk categories in
ARIC
low

High

1,045
1,244
CVD free
88
313
Incident CVD
1,133
1,557
Total
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
Correctly Classified
100.00%
0.00%
14.91%
>=low risk
78.05%
45.65%
50.48%
>=high risk
0.00%
100.00%
85.09%
> high risk
ROC
-Asymptotic Normal-Obs
Area Std. Err. [95% Conf. Interval]
------------------------------------------------------------

Total
2,289
401
2,690

LR+
1.0000
1.4362

2,690 0.6185
0.0116
0.59584 0.64124
Sensitivity= fraction of true positive cases
Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)
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LR0.4807
1.0000

Using the non-LB moderate risk category, the absolute CVD risk prevention
strategy has 1094 true negatives and 72 false negatives, along with 329 true positives and
1195 false positives as detailed in Table 17. The true and false positives (1524) contribute
to level II interventions because they receive the preventive interventions described in
Table 2 depending on absolute CVD risk score. The false positive category drives up
level II expenses while not preventing CVD events.
Table 17: Sensitivity/specificity analysis of the non-LB guided absolute CVD risk strategy
Any CVD event within first
12yrs of follow-up

Frozen non-LB based Framingham risk categories in ARIC

low
moderate
high
1,094
704
296
CVD free
72
120
93
Incident CVD
1,166
824
389
Total
Detailed report of sensitivity and specificity
Cut point
Sensitivity Specificity Correctly
Classified
100.00%
0.00%
14.91%
>=low risk (<10%)
82.04%
47.79%
52.90%
>=moderate risk (10-20%)
52.12%
78.55%
74.61%
>=high risk (20-30%)
28.93%
91.48%
82.16%
>=very high risk (>30% )
0.00%
100.00%
85.09%
> very high risk

very high

Total

195
116
311

2,289
401
2,690

LR+

LR-

1.0000
1.5716
2.4298
3.3957

0.3757
0.6096
0.7769
1.0000

ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------2,690 0.7061
0.0136
0.67938 0.73277
Sensitivity= fraction of true positive cases
Specificity= fraction of true negative cases
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)

When the moderate risk category of the LB Framingham algorithm was applied as
the treatment threshold, the absolute CVD risk prevention strategy guided by the
algorithm had 1,292 true negatives and 92 false negatives, along with 309 true positives
and 997 false positives as detailed in Table 18. The false and true negatives (1,384 cases)
did not contribute to level II expenses, since no preventive interventions were prescribed
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for this group. The false and true positives (1,306 cases) received the preventive
interventions described in Table 2 and hence contributed to level II expenses.
Table 18: Sensitivity/specificity analysis of the LB guided absolute CVD risk strategy
Any CVD event

Frozen lab based Framingham risk categories in ARIC

low
moderate
high
1,292
616
242
CVD free
92
128
86
Incident CVD
1,384
744
328
Total
Detailed report of sensitivity and specificity
Cut point
Sensitivity
Specificity
Correctly
Classified
100.00%
0.00%
14.91%
>=low risk (<10%)
77.06%
56.44%
59.52%
>=moderate risk (10-20%)
45.14%
83.36%
77.66%
>=high risk (20-30%)
23.69%
93.93%
83.46%
>=very high risk (>30% )
0.00%
100.00%
85.09%
> very high risk

very high

Total

139
95
234

2,289
401
2,690

LR+
1.0000
1.7692
2.7118
3.9013

LR-

0.4065
0.6582
0.8124
1.0000

ROC
-Asymptotic Normal-Obs
Area Std. Err.
[95% Conf. Interval]
-----------------------------------------------------------2,690 0.7077
0.0136
0.68097 0.73441

Whereas the true and false negatives in all programs do not contribute to level II
expenses because follow-up is not recommended, the false negative cases end up missing
the preventive interventions required to prevent CVD events. Treatment of CVD events
observed among the false negative cases contribute to level III expenses.
Level II expenses are subcategorized into costs associated with initial and followup office visits, and costs associated with the drugs prescribed by each preventive
strategy. These costs are discussed and calculated below. Although in clinical settings the
CPT coding varies depending on specific problems and complexity of the office visit, this
analysis assumed uniform complexity of all visits using CPT code 99203 that requires
medical decision making of moderate complexity. The visit typically lasts for 45 minutes
and includes face-to-face counseling and/or coordination of care with other providers
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(Centers for Medicare & Medicaid Services, 2015b). The 2015 physician office
reimbursement for CPT code 99203 was $100.28 in Mississippi (Centers for Medicare &
Medicaid Services, 2015c).
Costs associated with initial office visits
The initial office visits in this analysis are expected to occur immediately after
screening for all individuals who meet the treatment threshold. The initial office visits are
costed on an annual basis for each CVD prevention strategy in equation 2a-c below.
The individual CVD risk factors approach initial office visit costs:
For the individual risk factors approach, the initial visits included a total of 1557
individuals (true and false positives) who met the treatment threshold for the strategy
discussed above. The total costs of these initial office visits (IVrc) are estimated in
equation 2a:
𝑓(IVrc) = 1557 individuals ∗ 1 visit ∗ $100.28 = $156,135.96
The non-LB absolute CVD risk strategy initial office visit costs:
For the non-LB absolute CVD risk strategy, initial visits included a total of 1524
individuals (true and false positives) who met the treatment threshold. The total costs of
these initial office visits (IVac) are estimated in equation 2b:
𝑓(IVac) = 1524 individuals ∗ 1 visit ∗ $100.28 = $152,826.72
The LB absolute CVD risk strategy initial office visit costs:
For the LB absolute CVD risk strategy, initial visits included a total of 1,306 individuals
(true and false positives) who met the treatment threshold. The total costs of these initial
office visits (IVlc) are estimated in equation 2c:
𝑓(IVlc) = 1306 individuals ∗ 1visit/yr ∗ $100.28 = $130,965.68
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Costs associated with follow-up office visits
The follow-up office visits in this analysis were expected to occur after the initial
office visit for all positive cases in each program. The follow-up office visits were
scheduled at different intervals based on each individual’s absolute CVD risk score (for
the absolute CVD risk based programs) as summarized in Table 2, or as per the IDF and
ISH-ASH guidelines (for the individual risk factors program) outlined in Figure 3. The
follow-up office visits are detailed and costed on an annual basis for each CVD
prevention strategy in equation 3-5.
The individual CVD risk factors approach follow-up costs:
For the individual CVD risk factors strategy, follow-up office visits were only
relevant to individuals with diabetes and/or hypertension (high CVD risk category). Since
the IDF and ISH-ASH guidelines do not explicitly recommend a specific follow-up
regimen, this analysis used the follow-up schedule recommended by the American
Diabetes Association (ADA). The association recommends twice a year office visits for
diabetic patients with stable glycemic control (American Diabetes Association, 2014).
Follow-up for hypertension is assumed to follow the diabetes schedule. As explained
earlier, this analysis assumed similar complexity of all office visits. Therefore, all the
follow-up office visits were costed under CPT code 99203.
The high risk category (presence of diabetes and/or hypertension) identified 1557
true and false positive cases eligible for follow-up office visits scheduled every 6 months.
The annual costs for the office visits are estimated in equation 3 and shown in Table 19
as discounted costs.
FVrc = 1557 individuals ∗ 2 visits/yr ∗ $100.28 = $312271.92
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The non-LB absolute CVD risk strategy follow-up costs
Follow-up office visits includes 824 individuals in the moderate risk category,
389 in the high risk category and 311 in the very high risk category. The follow-up costs
(FVac) associated with each risk category are estimated in equations (4a-c) and
summarized in Table 19 as discounted costs.
For the moderate risk category (10-20%), 824 follow-up office visits for treatment
and CVD risk reduction discussion with a primary care provider are scheduled annually.
The annual cost for these office visits is estimated in equation 4a:
FVac−mod = 824 individuals ∗ 1 visit/yr ∗ $100.28 = $82630.72
For the high risk category (20-30%), 389 follow-up office visits for treatment and
CVD risk reduction discussion with a primary care provider are scheduled every 6
months. The annual costs for these office visits are estimated in equation 4b:
FVac−high = 389 individuals ∗ 2 visits/yr ∗ $100.28 = $78017.84
For the very high risk category (>30), 311 follow-up office visits for treatment
and CVD risk reduction discussion with a primary care provider are scheduled every 6
months. The annual costs for these office visits are estimated in equation 4c:
FVac−vhigh = 311 individuals ∗ 2 visits/yr ∗ $100.28 = $62374.16
Total annual cost of the follow-up office visits in all risk categories are calculated
by summation of equations 4a-c and shown in Table 19 as discounted costs.
∑ eq 3a−c = $82630.72 + $78017.84 + $62374.16 = $223,022.72
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The LB absolute CVD risk strategy follow-up costs
Follow-up office visits includes 744 individuals in the moderate risk category,
328 individuals in the high risk category and 234 individuals in the very high risk
category. The follow-up costs (FVlc) associated with each risk category are estimated in
equations 5a-c and summarized in Table 19 as discounted costs.
For the moderate risk category (10-20%), 744 Follow-up office visits for
treatment and CVD risk reduction discussion with a primary care provider are scheduled
annually. The annual costs for these office visits are estimated in equation 5a:
FVlc−mod = 744 individuals ∗ 1visit/yr ∗ $100.28 = $74608.32
For the high risk category (20-30%), 328 Follow-up office visits for treatment and
CVD risk reduction discussion with a primary care provider are scheduled every 6
months. The annual costs for these office visits are estimated in equation 5b:
FVlc−high = 328 individuals ∗ 2 visits/yr ∗ $100.28 = $65783.68
For the very high risk category (>30), 234 Follow-up office visits for treatment
and CVD risk reduction discussion with a primary care provider are scheduled every 6
months. The annual costs for these office visits are estimated in equation 5c:
FVlc−vhigh = 234 individuals ∗ 2 visits/yr ∗ $100.28 = $46931.04
Total annual cost of the follow-up office visits in all risk categories are calculated
by summation of equations 5a-c:
∑ eq 15a−c = $74608.32 + $65783.68 + $46931.04 = $187,323.04
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The annual costs associated with each year’s follow-up office visits are divided by
the 3% discounting rate discussed under the analysis framework. Therefore, in Table 19
the discounted annual costs for year 1 visits are divided by 1.031 and the costs for year
12 by 1.0312 to get the respective discounted total costs for follow-up office visits. All
costs are based on 2015 prices.
Table 19: Discounted costs of follow-up office visits: individual risk factors vs absolute
non-LB vs LB absolute risk approach
Individual CVD risk
factors approach
Discounted annual costs

non-LB absolute CVD
risk approach

LB absolute CVD risk
approach

Discounted annual costs

Discounted annual costs

Year 1

$303,177

$216,527

$181,867

Year 2

$294,346

$210,220

$176,570

Year 3

$285,773

$204,097

$171,427

Year 4

$277,450

$198,153

$166,434

Year 5

$269,369

$192,381

$161,586

Year 6

$261,523

$186,778

$156,880

Year 7

$253,906

$181,338

$152,311

Year 8

$246,510

$176,056

$147,875

Year 9

$239,330

$170,928

$143,568

Year 10

$232,360

$165,950

$139,386

Year 11

$225,592

$161,116

$135,326

Year 12

$219,021

$156,424

$131,385

$3,108,356

$2,219,969

$1,864,614

Year

Total

Annual visits=True & false positives adjusted by recommended frequency of follow-up visits annually
Discounted costs=Annual Follow-up costs discounted by (1.03) t where t= year 1 through 12
Source: Visits based on total annual office visits expected in the ARIC cohort based on their risk profile;
cost based on Medicare physician fees schedule for CPT code 99203.
Annual visits=True & false positives adjusted by recommended frequency of follow-up visits annually
Discounted costs=Annual follow-up costs discounted by (1.03) t where t= year 1 through 12
Source: Visits based on total annual office visits expected in the ARIC cohort based on their risk profile;
cost based on Medicare physician fees schedule for CPT code 99203.
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Costs associated with preventive interventions
Besides the follow-up office visits, each CVD prevention strategy has its own set
of preventive interventions as described in the methods section. The costs associated with
these preventive interventions are described below.
The Individual CVD risk factors strategy treatment expenses
i.

Antihypertensive therapy expenses:

The ISH-ASH guidelines recommend different treatment options depending on
the stage of hypertension (Weber et al., 2014). In stage I hypertension (BP>140/90),
monotherapy with either a thiazide-like diuretic or a CCB is recommended for blacks
with or without comorbid diabetes. In stage II hypertension (BP>160/100), combined
therapy is recommended with the second drug being an ACEI for individuals with
comorbid diabetes (Weber et al., 2014).
To ensure consistency in this analysis, the costing of the monotherapy treatment
outlined in Figure 3 was done using Hydrochlorothiazide 25mg/day, while the combined
therapy included Hydrochlorothiazide 25mg/day with Amlodipine 5mg/day in absence of
comorbid diabetes, or Hydrochlorothiazide 25mg/day with Lisinopril 10mg/day in
comorbid diabetes. The NADAC of Hydrochlorothiazide ((NDC 00143125601) is
$0.01192 per 25mg tablet, Lisinopril (NDC 00143126701) $0.02011 per 10mg tablet and
Amlodipine (NDC 76282023890) $0.01839 per 5mg tablet (Medicaid.gov, 2016).
For the individual CVD risk factors prevention program, the high risk category
(treatment threshold) included 1,419 individuals with blood pressure greater or equal to
140/90 mmHg. Of these individuals, 1,230 had stage I hypertension (BP ≥ 140/90 <
160/100mmHg) while 189 had stage II hypertension (BP ≥ 160/100mmHg).
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In the group with stage I hypertension, 959 individuals were diabetes free, while
271 had comorbid diabetes. The group with stage II hypertension had 134 diabetes free
individuals and 55 with comorbid diabetes. The annual costs for treating hypertension in
the high risk (DM/HTN) category are estimated in equations 6-7 and shown in Table 20
as discounted costs.
Stage I hypertension category was prescribed monotherapy with
Hydrochlorothiazide 25mg/day even if they had comorbid diabetes as explained above.
The annual costs for treating stage I hypertension are calculated in equation 6:
RxhtnI±𝑑𝑚 = 1230 individuals ∗ $0.01192 ∗ 365 days = $5351.484
Stage II hypertension category was prescribed combined therapy with addition of
Amlodipine or Lisinopril depending on whether or not they have comorbid diabetes as
explained above. The annual costs for treating stage II hypertension are calculated in
equation 7a-b.
Equation 7a: Combined antihypertensive therapy for hypertension stage II without
comorbid diabetes:
RxhtnII−𝑑𝑚 = 134 individuals ∗ $0.01192 + $0.01839 ∗ 365 days = $1482.4621
Equation 7b: Combined antihypertensive therapy for hypertension stage II with
comorbid diabetes:
RxhtnII+𝑑𝑚 = 55 individuals ∗ $0.01192 + $0.02011 ∗ 365 days = $643.00225
The total annual costs of antihypertensive therapy in the individual CVD risk
factor approach were calculated by summing up equations 6-7 and summarized in Table
20 as discounted costs.
∑ eq 6−7 = $5351.48 + $1482.46 + $643 = $7,476.9484
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ii.

Diabetes treatment and monitoring expenses

The IDF guidelines recommend initiating pharmacotherapy for type 2 diabetes at
the threshold of >7mmol/l (>126 mg/dL) as outlined in Figure 3. The recommended first
line oral hypoglycemic agent is metformin (IDF Clinical Guidelines Task Force, 2006).
To ensure consistency in this analysis, costing for diabetes treatment was done using the
common prescribed first line drug start dose, i.e. Metformin 850mg/day (NDC
00093104910). Metformin NADAC is $0.03292 per 850mg tablet (Centers for Medicare
& Medicaid Services, 2015a).
Although the frequency and intensity of glucose monitoring varies depending on
the plan of care, the IDF guidelines recommend periodic monitoring of glycated
hemoglobin (HbA1C) in all people with type 2 diabetes as part of comprehensive
management program (IDF Clinical Guidelines Task Force, 2006). In absence of an
explicit monitoring schedule by the IDF guidelines, this analysis assumed twice a year
monitoring of HbA1C in diabetic patients with stable glycemic control as recommended
by the ADA (American Diabetes Association, 2014). The costing for the HbA1C test was
done using CPT code 83036 QW ($13.22) in Mississippi as detailed under the absolute
CVD risk factor approach.
For the individual CVD risk factor approach, the high risk category (treatment
threshold) included 464 individuals with diabetes. The annual costs for treating and
monitoring type 2 diabetes are calculated in equation 8a-b.
Equation 8a: Cost of treating diabetes with Metformin:
Rxdma = 464 individuals ∗ $0.03292 ∗ 365 days = $5575.3312
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Equation 8b: The cost of monitoring diabetes using the HbA1C test:
HbA1C𝑡𝑒𝑠𝑡𝑎 = 464 individuals ∗ $13.22 ∗ 2 tests/year = $12268.16
The total annual costs of diabetes management in the individual CVD risk
approach were calculated by summing up equations 8a-b and summarized in Table 20 as
discounted costs.
∑ eq 8a−b = $5575.3312 + $12268.16 = $17843.491
iii.

Statin and Aspirin therapy:

In the individual CVD risk factor approach treatment with statin therapy was
recommended for diabetics at high risk for CVD based on risk appraisal that includes
measuring lipids and other metrics beyond the scope of this analysis. Anti-platelet
therapy was not routinely recommended except for individuals with prior CVD events
(not included in this analysis). Therefore, these two therapies were not included in the
costs of the approach based on treating individual risk factors (DM/HTN).
The non-LB absolute CVD risk strategy treatment costs:
The preventive interventions employed in the non-LB absolute CVD risk strategy
were based on the recommendations included in the WHO CVD prevention guidelines
discussed in the methods section and outlined in Table 2. Four preventive interventions
were costed: antihypertensive therapy, diabetes treatment and monitoring, statin therapy
and antiplatelet therapy with aspirin. These expenses are detailed below and summarized
as discounted costs in Table 20.
i.

Antihypertensive therapy expenses:

Antihypertensive therapy is recommended at different thresholds based on
systolic blood pressure and the patient’s absolute CVD risk score. For blacks, initial
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antihypertensive therapy should include monotherapy with a thiazide-like diuretic or a
CCB, which are preferred over ACEIs except in cases where hypertension coexists with
diabetes. Antihypertensive therapy for individuals with hypertension and diabetes should
include an ACEI combined with a thiazide-like diuretic because blacks have poor
response to ACEIs unless combined with a thiazide diuretic (World Health Organization,
2007).
To ensure consistency in this analysis, the costing of the hypertension treatments
outlined in Table 2 was done using the commonly prescribed first line drugs’ start doses,
i.e. Hydrochlorothiazide 25mg/day for hypertensive patients without diabetes, or
Lisinopril 10mg/day with Hydrochlorothiazide 25mg/day for hypertensive patients with
diabetes. Hydrochlorothiazide NADAC is $0.01192 per 25mg tablet, while Lisinopril is
$0.02011 per 10mg tablet (Medicaid.gov, 2016). The annual costs for antihypertensive
therapy are detailed in equations 9-11 and summarized in Table 20.
For the moderate risk category (10-20%), antihypertensive therapy was indicated
for 487 individuals with BP>=140/90, with 80 of them having co-existing diabetes. The
annual costs for the antihypertensive therapy in the moderate risk category are estimated
in equation 9a-b below:
Equation 9a: Hypertension without comorbid diabetes
Rxmodhtn−dm = 407 individuals ∗ $0.01192 ∗ 365 days = $1770.76
Equation 9b: Hypertension with comorbid diabetes
Rxmodhtn+dm = 80 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $935.28

For the high risk category (20-30%), antihypertensive therapy was indicated for
289 individuals with BP>=140/90, with 96 of them having co-existing diabetes. The
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annual costs for antihypertensive therapy in the high risk category/year is estimated in
equation 10a-b below:
Equation 10a: Hypertension without comorbid diabetes
Rxhighhtn−dm = 193 individuals ∗ $0.01192 ∗ 365 days = $839.70
Equation 10b: Hypertension with comorbid diabetes
Rxhighhtn+dm = 96 individuals ∗ ($0.01192 + $0.02011) ∗ 365days = $1122.33

For the very high risk category (>30%), antihypertensive therapy was indicated
for 301 individuals with BP>=130/80, with 150 of them having co-existing diabetes. The
annual cost for treating BP>=130/80 for the very high risk category/year is estimated in
equation 11a-b below:
Equation 11a: Hypertension without comorbid diabetes
Rxvhighhtn−dm = 151 individuals ∗ $0.01192 ∗ 365 days = $656.97
Equation 11b: Hypertension with comorbid diabetes
Rxvhighhtn+dm = 150 individuals ∗ ($0.01192 + $0.02011) ∗ 365days = $1753.64

The total annual costs of antihypertensive therapy in the non-LB absolute risk
strategy were calculated by summed up costs associated with the three risk categories and
shown in Table 20 as discounted costs.
∑ eq9−11 = $1770.76 + $935.28 + $839.70 + $1122.33 + $656.97 + $1753.64 = $7078.70

ii.

Diabetes treatment and monitoring expenses:

The WHO CVD prevention guidelines recommends pharmacotherapeutics
treatment for type 2 diabetes to commence at the same threshold (fasting >7mmol/l or
>126 mg/dL) for all risk categories (World Health Organization, 2007). The
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recommended first line oral hypoglycemic agent is Metformin 850mg/day (also used in
the individual risk factors strategy).
In the non-LB absolute CVD risk strategy, 431 individuals with diabetes met the
treatment threshold discussed above (absolute risk score>=10%). The annual cost for
treating type 2 diabetes (RxDM) in the moderate, high and very high absolute CVD risk
categories are calculated in equation 12a.
Equation 12a: Cost of treating diabetes with Metformin:
RxDM = 431 individuals ∗ $0.03292 ∗ 365 days = $5178.8098
Since the WHO CVD prevention guidelines do not give explicit recommendations
on the frequency of blood glucose monitoring for diabetics, in this analysis, monitoring
of HbA1C was assumed to occur twice a year during the recommended follow-up visits
and as recommended by the ADA. Costing for HbA1C testing was done using CMS
clinical diagnostic laboratory fee schedule for CPT code 83036 (also used in the
individual risk factors strategy). The annual cost for glucose monitoring (HbA1Ct) in the
three absolute CVD risk categories/year are calculated in equation 12b.
Equation 12b: Cost of monitoring diabetes with HbA1C test:
HbA1Ct = 431 individuals ∗ $13.22 ∗ 2 tests/year = $11395.64
The total cost of diabetes management in the three absolute CVD risk categories
were calculated by summing up equations 12a-b and summarized in Table 20 as
discounted costs.
∑ eq12𝑎−𝑏 = $5178.8098 + 11395.64 = 16574.45

104

iii.

Statin therapy expenses:

Treatment with statin therapy was only recommended for the very high risk
category (>30%) when there was no mechanism to assess lipid levels (see Table 2). To
ensure consistency in this analysis, costing was done using the common prescribed first
line drug start dose, i.e. atorvastatin 10mg/day (NDC 00378395005). Atorvastatin
NADAC is $0.10714 per 10mg tablet (Medicaid.gov, 2016).
The non-LB absolute CVD risk strategy put 311 individuals in the very high risk
category, hence qualifying them for statin therapy. The annual cost of the statin therapy
(Rxstatin) in the very high risk category/year was estimated in equation 13 and
summarized in Table 20 as discounted costs.
Equation 13: Cost of statin therapy:
Rxstatin = 311 individuals ∗ $0.10714 ∗ 365 days = $12162
iv.

Aspirin therapy expenses:

Treatment with aspirin therapy was only recommended for the very high risk
category (>30) as outlined in Table 2. To ensure consistency in this analysis, costing was
done using the common first line drug start dose, i.e. enteric coated aspirin 81mg/day
(NDC 00536100410). Aspirin NADAC is $0.01117 per 81mg tablet (Medicaid.gov,
2016).
The non-LB absolute CVD risk strategy put 311 individuals in the very high risk
category thus qualifying them for antiplatelet therapy. The annual cost of the Aspirin
therapy in the very high risk category/year was estimated in equation 14 and shown in
Table 20 as discounted costs.
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Equation 13: Cost of Aspirin therapy:
Rxasprin = 311 individuals ∗ $00.01117 ∗ 365 days = $1,267.9626
The non-LB absolute CVD risk strategy treatment costs:
The preventive interventions employed in the absolute CVD risk strategy guided
by the LB Framingham algorithm were based on the absolute CVD risk score and
followed the same pattern described under the non-LB absolute CVD risk strategy.
i.

Antihypertensive therapy expenses

Antihypertensive therapy was costed using the same recommendations and
thresholds described under the preventive strategy guided by the non-LB Framingham
algorithm. These expenses were calculated in equations 14-16 below and summarized in
Table 20 as discounted costs.
For the moderate risk category (10-20%), antihypertensive therapy was indicated
for 479 individuals with BP>=140/90, with 98 of them having co-existing diabetes. The
annual costs for the antihypertensive therapy in the moderate risk category/year are
estimated in equation 14a-b.
Equation 14a: Hypertension without comorbid diabetes
Rxmodlhtn−dm = 381 individuals ∗ $0.01192 ∗ 365 days = $1657.6548
Equation 14b: Hypertension with comorbid diabetes
Rxmodlhtn+dm = 98 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $1145.7131
For the high risk category (20-30%), antihypertensive therapy was indicated for
252 individuals with BP>=140/90, with 89 of them having co-existing diabetes. The
annual costs for antihypertensive therapy in the high risk category/year are estimated in
equation 15a-b.
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Equation 15a: Hypertension without comorbid diabetes
Rxhighlhtn−dm = 163 individuals ∗ $0.01192 ∗ 365 days = $709.1804
Equation 15b: Hypertension with comorbid diabetes
Rxhighlhtn+dm = 89 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $1040.495
For the very high risk category (>30%), antihypertensive therapy was indicated
for 200 individuals with BP>=130/80, with 108 of them having co-existing diabetes. The
annual cost for treating BP>=130/80 for the very high risk category/year are estimated in
equation 16a-b.
Equation 16a: Hypertension without comorbid diabetes
Rxvhighlhtn−dm = 92 individuals ∗ $0.01192 ∗ 365 days = $400.2736
Equation 16b: Hypertension with comorbid diabetes
Rxvhighlhtn+dm = 108 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $1262.622

The total annual cost of antihypertensive therapy in all the categories above were
calculated by summing equations 14-16 and summarized in Table 20 as discounted costs.
∑ eq14−16 = $1657.65 + $1145.71 + $709.18 + $1040.5 + $1040.5 +
$400.27 + $1262.62 = $7256.43
ii.

Diabetes treatment and monitoring expenses

In the LB absolute CVD risk strategy, 399 individuals with diabetes met the
treatment threshold (absolute risk score >=10%). The annual costs for treating and
monitoring type 2 diabetes (RxDMl) in the moderate, high and very high risk categories
are calculated in equations 17a-b.
Equation 17a: Cost of treating diabetes with Metformin:
RxDM𝑙 = 399 individuals ∗ $0.03292 ∗ 365 days = $4,794.30
Equation 17b: Cost of monitoring diabetes with HbA1C test:
HbA1Ctl = 399 individuals ∗ $13.22 ∗ 2 tests/yr = $10,549.56
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The total cost of diabetes management in the three risk categories were calculated
by summing up equations 17a-b and summarized as discounted costs in Table 20.
∑ eq17𝑎−𝑏 = $4,794.30 + $10,549.56 = $15,343.86
iii.

Statin therapy expenses

Treatment with statin therapy was recommended if total cholesterol was greater
than 8 mmol/l (309 mg/dL) for the moderate risk category, and greater than 5mmol/l (193
mg/dL) for the high risk category. In addition, everyone in the very high risk category
(>30%) was put on statin therapy irrespective of total cholesterol levels (see Table 2).
Based on these criteria, the LB absolute CVD risk strategy identified 25
individuals in the moderate risk category, 250 individuals in the high risk category and
234 individuals in the very high risk category as qualifying for statin therapy. Therefore,
a total of 509 individuals were put on statin therapy. The associated annual cost for statin
therapy are calculated in equation 18 and included as discounted costs in Table 20.
Equation 18: Cost of statin therapy
Rxstatin𝑙 = 509 individuals ∗ $0.10714 ∗ 365 days = $19,905
iv.

Aspirin therapy expenses

Treatment with aspirin therapy was only recommended for the very high risk
category (see Table 2). The LB absolute CVD risk strategy put 234 individuals in the
very high risk category thus qualifying them for antiplatelet therapy. The annual cost of
the Aspirin therapy in the very high risk category was calculated in equation 19 and
summarized as discounted costs in Table 20.
Equation 19: Cost of Aspirin therapy
Rxasiprin = 234 individuals ∗ ($00.01117 ∗ 365 days) = $954.0
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Table 20: Discounted costs of preventive interventions: Individual risk factors vs non-LB
vs LB absolute CVD risk programs
Year

Individual CVD risk factor
Non-LB Absolute CVD risk program
LB Absolute CVD risk program
program
DM
BP
DM
Statin Aspirin Discounted
BP
DM
Statin Aspirin Discounted
Discounted
therapy cost /year therapy therapy therapy therapy cost/year therapy therapy therapy therapy cost/year

Year 5

Year 4

Year 3

Year 2

$6,262

$6,450

$6,643

$6,842

$7,048

$7,259

$14,508

$14,944

$15,392

$15,854

$16,329

$16,819

$17,324

$20,588

$21,205

$21,842

$22,497

$23,172

$23,867

$24,583

$5,588

$5,756

$5,928

$6,106

$6,289

$6,478

$6,672

$6,873

$13,084

$13,477

$13,881

$14,297

$14,726

$15,168

$15,623

$16,092

$9,601

$9,889

$10,185

$10,491

$10,806

$11,130

$11,464

$11,808

$1,001

$1,031

$1,062

$1,094

$1,127

$1,160

$1,195

$1,231

$29,274

$30,152

$31,057

$31,988

$32,948

$33,936

$34,954

$36,003

$5,728

$5,900

$6,077

$6,259

$6,447

$6,641

$6,840

$7,045

$12,113

$12,476

$12,850

$13,236

$13,633

$14,042

$14,463

$14,897

$15,713

$16,185

$16,670

$17,170

$17,685

$18,216

$18,762

$19,325

$753

$776

$799

$823

$848

$873

$899

$926

$34,307

$35,336

$36,397

$37,488

$38,613

$39,771

$40,965

$42,194

BP
therapy

Year 6
$6,079
$19,988

Year 1

Year 7
$14,086

$32,338

$5,902

$710

$31,396

Year 8

$14,811

$689

$30,481

$33,308
$11,417

$14,380

$669

$731
$5,399

$11,085

$13,961

$15,256
$27,593

$5,242

$10,762

$11,760
$943

$26,790

$5,090

$5,561
$9,050

$916

$26,009

$28,421
$12,333

$8,786

$889

$972

$5,267

$11,974

$8,530

$432,594

$9,321

$18,841

$5,114

$11,625

$9,496

$12,703

$13,277
$18,292

$4,965

$72,231 $152,733 $198,134

$5,425

$5,564
$12,891
$17,759

$369,125

$19,406

Year 10
$5,402
$12,515

$70,461 $164,982 $121,061 $12,621

$13,676

Year 11
$5,244

$252,040

$5,730

Year 12
$74,426 $177,614

Year 9

Total

BP, DM, Statin & Asprin therapies are the discounted annual costs of therapy for hypertension, diabetes, cholesterol and platelets respectively, calculated by
multiplying the at-risk ARIC sample that was eligible for therapy with the NADAC of the drug (s) recommended by each CVD prevention program
Discounted cost/year sums up the discounted costs of all therapies prescribed to the at-risk ARIC sample annually
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Summary of level I and II expenses
The total costs of screening and preventive interventions prescribed for the true
and false positives in the individual CVD risk factor program (CRxrjt) were calculated by
summing up the costs of screening (eq. 1a), initial (eq. 2a) and follow-up (Table 19)
office visits, and cost of pharmacotherapeutics (Table 20) as detailed below:
CRxrjt = $14,634 + $156,135.96 + $3,108,356 + $252,040 = $3,531,165.96
The total costs of screening and preventive interventions prescribed for the true
and false positives in the non-LB absolute CVD risk program (CRxajt) were calculated by
summing up the costs of screening (eq. 1b), initial (eq. 2b) and follow-up (Table 19)
office visits, and cost of pharmacotherapeutics (Table 20) as detailed below:
CRxajt = $20,686 + $152,826.72 + $2,219,969 + $369,125 = $2,762,606.72
The total costs of screening and preventive interventions prescribed for the true
and false positives in the LB absolute CVD risk program (CRxljt) were calculated by
summing up the costs of screening (eq. 1c), initial (eq. 2c) and follow-up (Table 19)
office visits, and cost of pharmacotherapeutics (Table 20) as detailed below:
CRxljt = $66,631.3 + $130,965.68 + $1,864,614 + $432,594 = $2,494,804.98
Level III: Expenses in treating false negatives cases
The cost of secondary prevention interventions associated with each CVD
prevention strategy was dependent on the sensitivity of the screening algorithm used. A
screening algorithm with low sensitivity led to a high number of false negatives requiring
treatment and rehabilitation services for the CVD events occurring in the group. Since the
initial follow-up in ARIC did not include the survival status of each incident CVD event,
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costing level III expenses was done using the average costs associated with CVD events
in general rather than the average cost for specific CVD events.
Although the costs associated with treating the CVD events included in this study
vary greatly within the US, this analysis used the estimated direct average initial and
follow-up costs for treating CVD events in the US published by Chapman and colleagues
in 2011 (Chapman, Liu, Girase, & Straka, 2011). In their retrospective matched cohort
analysis of commercially insured managed care population, Chapman et al. (2011)
estimated that initial inpatient management of a CVD event would have an average cost
of $16,981 (SD $20,474), while the first year follow-up costs would average $16,582 (SD
$34,425) per case.
Due to data limitations, this analysis estimated level III expenses using these
average direct medical and pharmacological expenses published by Chapman et al.
(2011) despite the expected great variation in event specific costs. Although Chapman et
al. (2011) demonstrated that the follow-up costs would increase in subsequent years of
follow-up, this analysis assumed a constant yearly follow-up cost of $16,582 per incident
CVD. The initial treatment costs and follow-up expenses of the false negatives associated
with the non-LB and individual CVD risk factor approaches were depended on the year
in which each event occurred.
To calculate level III expenses (CUSE), the false negative cases in each year were
multiplied by the discounted average cost of initial management of a CVD event (i.e.
𝑡
icost =12
1 [False negative cases ∗ $16,981/1.03 ]) and then the discounted average yearly

follow-up costs were added for every subsequent follow-up year, through year 12 (i.e.
𝑡
 =12
1 [False negative cases ∗ $16,582/1.03 ]). For instance, the non-LB absolute CVD
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risk approach was associated with 3 false negatives in year one. The discounted initial
costs for year one was: 3 individuals ∗ $16,981/1.031 = $49,459.22 . The follow-up costs
for these events was the sum of the discounted follow-up costs for each of the subsequent
years of follow-up (see Table 21).
Table 21: Initial & follow-up costs for treating false negative cases by prevention strategy

Year

Individual CVD risk
factors program
Discounted Discounted
initial costs
f/up costs

non-LB absolute CVD risk
program
Discounted
Discounted
initial costs
f/up costs

LB absolute CVD risk
program
Discounted Discounted
initial costs
f/up costs

Yr 1

$65,946

$660,229

$49,459

$495,172

$49,459

$495,172

Yr 2

$80,031

$744,791

$32,012

$297,917

$48,019

$446,875

$46,620

$399,984

$62,160

$533,313

$77,700

$666,641

Yr 4

$75,437

$590,766

$75,437

$590,766

$60,350

$472,613

Yr 5

$117,184

$827,363

$58,592

$413,681

$87,888

$620,522

Yr 6

$85,328

$534,700

$42,664

$267,350

$71,107

$445,583

Yr 7

$27,614

$150,459

$69,036

$376,147

$69,036

$376,147

Yr 8

$160,859

$740,961

$160,859

$740,961

$174,264

$802,708

Yr 9

$91,102

$340,597

$65,073

$243,284

$104,116

$389,254

Yr 10

$138,990

$395,428

$88,448

$251,636

$113,719

$323,532

Yr 11

$159,477

$306,923

$147,209

$283,314

$147,209

$283,314

Yr 12

$142,922

$139,563

$119,101

$116,303

$226,293

$220,975

Total

$1,191,509

$5,831,766

$970,051

$4,609,843

$1,229,159

$5,543,336

Yr 3

Discounted initial costs have been calculated by multiplying false negative cases with the discounted average cost of
initial management of CVD ($16,981/1.03t) published by Chapman et al. (2011).
Discounted follow-up (f/up) costs have been calculated by multiplying false negative cases each year with the
discounted annual follow-up cost in subsequent years using the average cost of the first year of CVD follow-up
($16,582/1.03t) published by Chapman et al. (2011).
False negatives are calculated from ARIC data based on the sensitivity/specificity of the screening method used
described in Tables 17-19.
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Summary of level III expenses
The total costs of treating false negative cases in the individual CVD risk factors
program (CUSErjt) were calculated by summing up the initial and follow-up costs in
Table 21.
CUSErjt = $1,191,509 + $5,831,766 = $7,023,275
The total costs of treating false negative cases in the non-LB absolute CVD risk
program (CUSEajt) were calculated by summing up the initial and follow-up costs in
Table 21.
CUSEajt=$970,051 + $4,609,843 = $5,579,894
The total costs of treating false negative cases in the LB absolute CVD risk
program (CUSEljt) were calculated by summing up the initial and follow-up costs in
Table 21.
CUSEljt=$1,229,159 + $5,543,336 = $6,772,495

Outcomes associated with the three prevention programs
Ideally, the effectiveness of a disease prevention program depends on the
accuracy of the screening method used, and the potency of the prescribed preventive
interventions. However, due to data limitations, this analysis assumed that the preventive
interventions prescribed under the individual risk factors and absolute CVD risk
approaches to CVD prevention were equally potent in preventing the true CVD cases
identified by the respective screening methods. Therefore, the number of prevented CVD
events for each preventive strategy were dependent on the sensitivity/specificity of its
screening algorithm at its optimal risk threshold.
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In the context of this analysis, sensitivity denotes the proportion of the observed
(true) CVD cases that were correctly identified as positive (high risk) by a screening
algorithm at baseline. On the other hand, specificity is the proportion of true CVD free
cases that were correctly identified as negative (low risk) by a screening algorithm at
baseline.
The individual risk factors approach focusing on screening for diabetes and/or
hypertension had its optimal balance of sensitivity/specificity at the high risk (presence of
diabetes and/or hypertension) threshold where sensitivity is 78.05% and specificity
45.65% as detailed in Table 16. This implies that when individuals with diabetes and/or
hypertension are considered as positive cases, about 78% of all individuals who would
end up experiencing CVD events during follow-up were identified at baseline. At the
same time, about 56% if individuals who did not end up developing CVD events are
misclassified as positive and hence unnecessarily put on preventive interventions.
The non-LB Framingham algorithm had its optimal balance of
sensitivity/specificity at the moderate risk (10-20%) threshold where sensitivity was
82.04% and specificity 47.79% as detailed in Table 17. This implies that when
individuals with >=10% absolute CVD risk score were considered as positive cases,
about 82% of all individuals who would end up experiencing CVD events during followup were correctly identified at baseline. At the same time, about 52% if individuals who
did not end up developing CVD events were misclassified as positive cases.
The LB Framingham algorithm had its optimal balance of sensitivity/specificity at
the moderate risk (10-20%) threshold where sensitivity was 77.06% and specificity
56.44% as detailed in Table 19. This implies that when individuals with >=10% absolute
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CVD risk score were considered as positive cases, about 77% of all individuals who
would end up experiencing CVD events during follow-up were correctly identified at
baseline. At the same time, almost 44% if individuals who did not end up developing
CVD events were misclassified as positive cases.
True positive cases that occurred later during follow-up were weighted less than
those occurring early in the follow-up using the annual discounting rate of 3% discussed
under the analysis framework. Table 22 summarizes the discounted true positives
(predicted true CVD events) for each program.
Table 22: True positive cases stratified by CVD prevention program

Observed CVD
events

Individual CVD risk
factors program
Predicted true CVD
events

non-LB absolute
CVD risk program
Predicted true CVD
events

LB absolute CVD
risk program
Predicted true CVD
events

Year

actual

discounted

actual

discounted

actual

discounted

actual

discounted

Yr 1

20

19

16

16

17

17

17

17

Yr 2

23

22

18

17

21

20

20

19

Yr 3

30

27

27

25

26

24

25

23

Yr 4

31

28

26

23

26

23

27

24

Yr 5

33

28

25

22

29

25

27

23

Yr 6

33

28

27

23

30

25

28

23

Yr 7

35

28

33

27

30

24

30

24

Yr 8

48

38

36

28

36

28

35

28

Yr 9

36

28

29

22

31

24

28

21

Yr 10

32

24

21

16

25

19

23

17

Yr 11

37

27

24

17

25

18

25

18

Yr 12

43

30

31

22

33

23

24

17

Total

401

327

313

257

329

270

309

254

Observed events are the CVD events that occurred each year in the at risk ARIC cohort
Predicted true CVD events are the true positive cases calculated from ARIC data based on the
sensitivity/specificity of the screening method used
Discounted cases are the true positive cases multiplied by annual discounting rate (1.03) t where t= year 1
through 12
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Average and incremental cost effectiveness
The average cost-effectiveness ratio
The average cost-effectiveness of each CVD prevention approach is a function of
the net costs divided by net benefits associated with each program. These equations are
described in equations 22-24.
Equation 22: The individual CVD risk factors program.
∆TCr
∆Er

=

[$3,531,166+$7,023,275]
[257]

=

$10,554,441
257 true positives

=

$41,068
1 true positve

Equation 23: The non-LB absolute CVD risk program.
∆TCa
∆Ea

=

[$2,762,607+$5,579,894 ]
[270]

=

$8,342,501
270 true positives

=

$30,898
1 true positive

Equation 24: The LB absolute CVD risk program.
∆TCl
∆El

=

 [$2,494,805+$6,772,495 ]
[254]

=

$9,267,300
254 true positives

=

$36,485
1 true positive

Overall, the individual risk factors and LB absolute CVD risk
programs had their cost-effectiveness ratios higher by 25% and 14%
respectively compared to the non-LB absolute CVD risk program.
Compared to the non-LB absolute CVD risk program, the 12-year
discounted costs were 21% and 9% greater in the individual risk factors and
LB absolute CVD risk programs respectively. Both programs identified 5%
and 6% fewer cases respectively compared to the non-LB absolute CVD risk
program.
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The incremental cost-effectiveness ratio
The incremental cost-effectiveness ratio was calculated by populating the ICER
model with the costs and outcomes discussed in the above sections. For each CVD
prevention strategy, the costs were calculated by adding the costs of screening, initial
visit, discounted follow-up visits, and the discounted cost of preventive treatments
prescribed (CRx), and the cost of treating false negatives (CUSE). The outcomes for each
CVD prevention strategy were calculated as the discounted true positive cases and
constitutes CVD events which could be prevented through early detection of risk
depending on the screening algorithm used.
The incremental cost effectiveness ratio (ICER) of the non-LB absolute CVD risk
approach versus the individual CVD risk factor approach is calculated in equation 25.
Equation 25: ICER=
∆TCa−r
∆Ea−r

=

j=2
1 [$2,762,607+$5,579,894 −$3,531,166−$7,023,275]
[270−257]

=

−$2,211,9401
+13 true positives cases

Interpretation: The non-LB absolute CVD risk approach would cost $2 million
less over 12 years to identify 13 more actual CVD cases than the individual risk factors
approach. For every extra case that the non-LB approach identifies, it saves $170,000.
Hence, the non-LB approach completely dominates the individual risk factors approach
in both costs and predictive ability.
The incremental cost effectiveness ratio (ICER) of the non-LB absolute CVD risk
approach versus the LB absolute CVD risk approach is calculated in equation 26.
Equation 26: ICER=
∆TCa−l
∆Ea−l

=

j=21 [$2,762,607+$5,579,894 −$2,494,805−$6,772,495 ]
−$924,799
=
[270−254]
+16 true positve cases
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Interpretation: The non-LB absolute CVD risk approach would cost $900,000 less
over 12 years to identify 16 more actual CVD cases than the LB absolute CVD risk. For
every extra case that the non-LB approach identifies, it saves $58,000. Hence, the nonLB approach completely dominates the LB approach in both costs and predictive ability.
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CHAPTER 5
DISCUSSION
The overarching goal of this study was to externally validate and determine the
cost-effectiveness of the non-LB Framingham algorithm in the multi-racial ARIC dataset.
Validating and costing the non-LB Framingham algorithm in a multiracial sample with
high representation of individuals who self-report black race was postulated to be an
important step in availing a risk assessment tool that could guide CVD prevention in
resource constrained settings. Important results discussed in this chapter include; the
influence of social determinants of health on CVD risk assessment, and comparative
predictive performance and cost-effectiveness of non-LB Framingham Algorithm.
Social determinants of health and CVD risk assessment
The conditions in which individuals are born, grow, live, work and age are known
to play an important role in the evolution of many diseases including CVD (Will et al.,
2011). These social determinants of health are particularly influential in attenuating or
exacerbating manifestation of the modifiable CVD risk factors included in this study.
Risk assessment algorithms, such as the non-LB Framingham, that incorporate risk
factors which are shaped by social determinants of health require an evaluation of
relevance and validity before they are generalized across populations.
The organizing framework used in this study appreciates the modulating impact
of the social determinants of health on CVD risk and provides a basis for examining the
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comparability of effects of CVD risk factors in the white versus black US
population. Since the social determinants of health are in part driven by distribution of
resources, the framework also sets the stage for evaluating the feasibility of various CVD
risk assessment strategies in resource constrained settings.
Incidence of CVD by sex and race
The statistical differences between the eligible and ineligible samples are expected in
this kind of study. Since over 81% of the ineligible sample was excluded due to prevalent
CVD at baseline, it is expected that CVD risk factors in this group was significantly
higher than the eligible sample which was free of CVD at baseline. The higher
percentage of blacks in the ineligible sample (36%) compared to the eligible sample
(23%) is consistent with the known higher burden of CVD in this population.
In the entire ARIC cohort, the incidence rate of CVD was lower but comparable to
the Framingham cohort (11.1 versus 11.5 cases per 1000 person-years respectively).
white women in the ARIC dataset had a significantly lower incidence rate compared to
their counterparts in the Framingham cohort (6.5 versus 8.4 cases per 1000 person-years
respectively). On the other hand, white men in the ARIC cohort had a higher incidence
rate compared to men in the Framingham cohort (15.5 versus 15.1 cases per 1000 personyears respectively).
The factors associated with the disparate incidence rates between the two cohorts
could be multifaceted. One potential factor may be the manner in which the CVD
variable is operationalized in the two studies. In the Framingham dataset the CVD
variable included CHD, heart failure, stroke and peripheral vascular disease, however the
latter variable was not included in the ARIC incidence data provided by NHLBI. As a
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result, the CVD variable in ARIC does not capture incident peripheral vascular disease. If
the incidence rate of peripheral vascular disease in the Framingham dataset (1.2 and 2.2
cases per 1000 person-years in women and men respectively) were to be applied in the
ARIC cohort, the white women’s CVD incidence rate would increase slightly and be
comparable to the rate in Framingham cohort, while white men would have a
significantly higher CVD incident rate.
The different incident rates among white men in ARIC versus Framingham may also
be as a result of variation in sample characteristics. Since ethnicity was not reported in
the ARIC dataset, there may be unaccounted differences in CVD incidence by ethnicity.
Correspondence with NHLBI clarified that Hispanics in the ARIC sample were coded as
black or white depending on their self-reported racial group.
The similarity between the incidence proportion of CVD among white and black men
in ARIC (18.6% and 18.8% respectively, p=0.900) is atypical since black men have been
reported to have a higher incidence of CVD (R. Cooper et al., 2000; Mozaffarian et al.,
2015). If there were a significant number of Hispanic individuals in the ARIC cohort, this
could have a negative effect on the discrimination and calibration since the Framingham
algorithms are generally known to perform poorly among Hispanics (Beswick et al.,
2008).
Performance of the non-LB Framingham CVD risk assessment algorithm
After confirming that all covariates included in the non-LB and LB Framingham
models met the proportionality of hazard assumption, and there was no significant
multicollinearity between variables, sex specific Cox regression was used to test the
mathematical performance of the Framingham models in the ARIC dataset. Use of sex
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specific models was critical because CVD risk factors are known to have different effect
sizes among women and men. Just as reported in the Framingham dataset, the unadjusted
non-LB and LB Framingham models were comparable in discrimination and calibration,
and their performance was superior in women compared to men in the ARIC dataset.
Among women, both the non-LB and LB Framingham models performed well,
but among men, discrimination was low and calibration was poor for both models. The
comparable performance of the non-LB and LB Framingham models in both sexes
suggest that BMI could be an adequate proxy for HDL and total cholesterol in both sexes.
The similar performance of both the non-LB and LB Framingham models in the white
and black cohorts collaborates previous studies which have reported optimal performance
of Framingham algorithms in the US black population.
The discrimination of risk among women in ARIC was within the confidence
interval reported in the Framingham dataset for the published non-LB (95% CI, 0.760.81) and LB Framingham models (95% CI, 0.77-0.81). However, risk discrimination
among men was significantly lower. The underperformance of the models among men in
the ARIC dataset suggest that the independent variables used to predict CVD risk in the
Framingham dataset do not capture the full extent of risk among men in the ARIC
dataset. This phenomenon necessitates further analysis to examine the effect of the
Framingham derived risk factors in the ARIC cohort, and additional or alternative
variables which may improve the performance of the non-LB Framingham models.
Evaluation of the effect and impact of the Framingham derived risk factors in the
ARIC cohort was done by comparing the regression coefficients from the models
generated in the ARIC dataset to those reported from the Framingham dataset using the z
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score formulae. Overall, all the covariates in the non-LB and LB models had similar
effect and impact in the black cohort, but smoking and diabetes had a different effect in
the white cohort. The impact of smoking was higher among white women but lower
among white men, while diabetes had a higher impact among white men in ARIC
compared to the Framingham dataset. These differences pinpoint potential causes of the
low performance of the non-LB and LB Framingham models among men. Since white
men constituted 79% of the male sample in the ARIC cohort, the comparative low impact
of smoking on CVD risk in this group may have affected the overall performance of the
models among men. The differences also suggest that additional or alternative variable(s)
may have a stronger explanatory power on CVD risk compared to smoking.
The equivalence of effect of the Framingham generated risk factors in ARIC’s
black cohort suggests that the general CVD Framingham algorithms are applicable to the
US black population. This applicability mirrors what has been reported with earlier
versions of Framingham algorithms which focused on hard coronary events and were
validated in black datasets (D'Agostino RB, Grundy, Sullivan, Wilson, & CHD Risk
Prediction Group, 2001a). The semblance of effect of the traditional CVD risk factors in
the black ARIC dataset and the white Framingham dataset also supports the widely
accepted premise that traditional CVD risk factors have a fairly similar effect and impact
across populations (Yusuf et al., 2004). These results contribute to the body of knowledge
pertaining to CVD epidemiology in the black dataset and provide an evidence based
foundation upon which research on novel risk factors hypothesized to have a unique
impact in the black population could be added and tested.
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When more CVD risk factors were added to the non-LB and LB Framingham
models, there was no significant improvement in discrimination or calibration. In fact,
adding more risk factors to the non-LB model (family history of premature CHD and
waist hip ratio) and the LB model (BMI, waist hip ratio, family history of premature
CHD, and apolipoprotein A and B) tended to increase the confidence interval of their C
statistic without meaningful improvement in discrimination or calibration. The lack of
significance suggests that the impact of these additional risk factors is mediated by the
traditional risk factors already included in the published Framingham models.
It is worth noting that some Framingham risk factors lost their statistical
significance when additional risk factors were included. For instance, waist hip ratio
replaced BMI as the significant variable in the adjusted non-LB model for all cohorts
except among white women. Similarly, waist hip ratio replaced total cholesterol as the
significant variable in the adjusted LB model among black women and men, and was
significant among white men without affecting the significance of total cholesterol.
The differential effect of body mass across populations has been reported
previously. For instance, the association between high BMI and CVD mortality has been
reported as stronger in white women than in black women (Abell et al., 2007). These
racial differences in the effect of BMI were apparent in this analysis. Among the non-LB
Framingham risk factors, BMI had a marginally lower effect on black women and men in
the ARIC (β=0.668 and 0.631 respectively) compared to white women and men (β=
0.797 and 0.793 respectively) in the ARIC dataset.
Stepwise regression analysis revealed that other covariates in the non-LB model
(diabetes, systolic blood pressure, antihypertensive therapy, smoking and age) had

124

adequate discrimination among black women (C=0.7426) and BMI added no significant
improvement (C=0.7452) to the CVD prediction model. Waist hip ratio had a slightly
better effect than BMI among black women (C=0.7481). The waning effect of BMI when
other traditional risk factors are held constant is consistent with the findings reported by
Abell and colleagues. The study demonstrated that the association between obesity and
CVD mortality was no longer significant among black women when hypertension, total
cholesterol, diabetes, age and smoking status were controlled (Abell et al., 2007).
These findings add to the body of literature suggesting that BMI may not be an
optimal CVD risk indicator, and its effect could be mediated in part by other related risk
factors such as hypertension and diabetes. Although BMI continues to be widely used as
the metric for diagnosing overweight and obesity, there is a growing body of literature
describing its limitations. Whereas BMI is an indicator total body fat, the metric does not
take into consideration how the fat is distributed within the body (Simon, 2009). From a
cardiovascular standpoint, abdominal fat is more dangerous than any other fat in the
body.
The slightly better performance of the waist hip ratio in the non-LB and LB
adjusted models also adds to the body of evidence suggesting that measures of central
adiposity may be more relevant in predicting CVD compared to measures of body mass.
The strong predictive power of central obesity has been reported by many studies
including the INTERHEART study where investigators demonstrated a strong link
between increased waist hip ratio and the risk of heart attack even after controlling for the
traditional CVD risk factors. In the same study, BMI lost its modest association with
myocardial infarction after adjusting for traditional risk factors (Yusuf et al., 2005).
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Despite the growing evidence supporting the significant role of central adiposity
in predicting CVD, most of the existing non-LB algorithms have not included it as a
covariate. Possible reasons for this may include the reported difficulties associated with
assessing and reproducing the waist hip ratio measure (Simon, 2009). Over the last
decade, waist circumference has been suggested as an alternative measure of central
adiposity that still has a strong link to the risk of myocardial infarction, but is relatively
easier to reproduce (Simon, 2009; Yusuf et al., 2005).
The strong effect of central adiposity on CVD risk in the black population, and
the superiority of waist hip ratio and circumference in predicting CVD provide insights
on potential pathways to improve the non-LB Framingham algorithm. Replacing BMI
with a measure of central adiposity such as waist circumference and testing the model in
a large homogeneous black cohort could provide important data on the additional value
of the measure in predicting absolute CVD risk. Other measures which could be helpful
include the ankle brachial index which is used to diagnose peripheral vascular disease.
Testing this measure in a homogeneous black cohort with peripheral vascular disease
included in the CVD variable may provide insights as to whether it has any extra value in
optimizing risk prediction of the non-LB Framingham algorithm. Evaluating the effect
and impact of ankle branchial index was not possible in this study since peripheral
vascular disease was not included in the CVD variable.
Comparative performance in risk stratification
The comparable performance of the published non-LB and LB Framingham
algorithms in actual risk stratification of the ARIC dataset complements the similarities
observed in the mathematical performance. The high overall agreement (92.76%) and
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substantial kappa statistic (0.76) suggest that the two algorithms are very comparable in
stratification of risk. Stratification of the cohort in the high and very high risk categories
was essentially the same for both algorithms, but the LB algorithm placed slightly more
individuals in the low risk category. Both algorithms placed a greater proportion of men
and blacks in higher risk categories, a trend which is consistent with current published
CVD epidemiology (Mozaffarian et al., 2015).
The agreement between the non-LB and LB versions of the recalibrated and the
adjusted algorithms derived in ARIC were also high. However, the recalibrated and
adjusted algorithms placed a significantly greater percentage of the ARIC population in
the low risk category compared to the published Framingham non-LB algorithm. This
discordance in risk stratification necessitated sensitivity and specificity analysis to
determine the clinical usefulness of the non-LB Framingham algorithm, and its
comparison with the alternative algorithms discussed above.
The comparability of the non-LB and LB Framingham algorithm AUROC curves
(0.706 vs 0.71 respectively) further adds to the evidence that HDL and total cholesterol
may not add significant marginal value to CVD risk prediction especially in the black
population. Since AUROC curves usually depict the percentage of randomly selected
pairs for which the test correctly classifies as normal or abnormal, the AUROC of the
non-LB algorithm manifest better performance in the ARIC dataset compared to other
alternatives. The higher AUROC of the published non-LB Framingham algorithm
compared to those of the recalibrated and adjusted algorithms suggest that the non-LB
Framingham algorithm could be ready for use ‘as is’ in the US black population.
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The suboptimal performance of the calibrated non-LB (AUROC=0.67) and LB
(AUROC=0.69) based algorithms indicate that ARIC derived survival and mean of risk
factors are not better substitutes for those generated in Framingham. This could be as a
result of the unmeasured confounders discussed earlier, which may also have contributed
to the low performance of the adjusted non-LB (AUROC= 0.68) and LB (AUROC= 0.69)
based models. It is important to note that inclusion of up to 9 covariates in the adjusted
algorithm did not make much difference in its predictive ability.
Sensitivity/specificity analysis also revealed that the non-LB Framingham
algorithm had a slightly better sensitivity but poorer specificity compared to the LB
algorithm. For instance, at the high risk threshold (20-30%), the non-LB Framingham
algorithm had sensitivity/specificity ratios of 0.25/0.95 for women and 0.51/0.73 for men.
The LB Framingham algorithm sensitivity/specificity ratios were 0.23/0.95 for women
and 0.50/0.75 for men respectively.
In the Framingham dataset, the non-LB algorithm was both slightly less sensitive
and specific compared to the LB algorithm. For example, at 20% risk threshold,
sensitivity/specificity ratios were 0.58/0.83 for women and 0.48/85 for men versus
0.60/0.84 for women and 0.49/85 for men in the non-LB and LB algorithms respectfully.
(D'Agostino RB et al., 2008). These ratios indicate that in the ARIC dataset, preventive
interventions should be initiated at least at the moderate risk category because more
individuals who will end up developing events (true positives) was misclassified as not
at-risk (false negatives) if the high risk category was adopted as the treatment threshold.
Whereas the tradeoff between sensitivity and specificity are often delicate, a nonLB algorithm with slightly higher sensitivity could be very important in helping early
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detection of risk in the black population that carries the highest burden of CVD in the US.
In fact, depending on availability of resources and the risk/benefit tradeoff of preventive
treatments, a risk threshold such as the moderate risk category (10-20%) may be more
beneficial since the non-LB Framingham algorithm would have a better overall
sensitivity/specificity ratio (0.77/0.57) if selected as the treatment threshold in the black
population.
Cost-effectiveness of non-LB Framingham Algorithm
In the cost-effectiveness analysis where the individual CVD risk factors approach
focusing on treating diabetes and/or hypertension was considered as the status quo, the
non-LB absolute CVD risk approach helped detect more true CVD cases at a lower cost.
The individual risk factors approach had a 25% higher average cost-effectiveness ratio.
Over the 12year follow-up period, the discounted costs were 21% greater in the
individual risk factors approach and 5% fewer CVD cases were identified.
Whereas the cost of screening and preventive interventions was higher in the nonLB approach, the cost of follow-up visits and treating CVD in false negative cases was
very high in the individual CVD risk factor approach. The high follow-up costs are as a
result of a higher number of true and false positives, and the ‘one size fits all’ approach
taken by the individual CVD risk factor strategy. Individuals with hypertension and/or
diabetes were scheduled for the minimum 2 visits per year recommended by the ADA
guidelines. Ref The non-LB absolute CVD risk approach grades the number of follow-up
visits based on the absolute risk score. Individuals with absolute CVD risk core below 20
are scheduled for a minimum 1 annual visit, while those with higher scores are scheduled
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for 2 visits per year. The graded approach and the fewer true and false positive cases
scheduled for follow-up by the non-LB approach makes the approach cost-effective.
The high number of discounted false negatives associated with the individual risk
factors approach (13 more) further increased the costs associated with the approach due
to the downstream expenditure of treating the resultant CVD cases. These downstream
expenses make a strong case why using a risk assessment approach with high sensitivity
and specificity is important. As illustrated in the methods section, clustering of multiple
CVD risk factors is known to have an additive and synergistic effect that is not well
captured by aggregating individual risk factors. The false negatives associated with the
individual CVD risk factor approach occur early and are costed using lightly discounted
treatment costs.
The higher expenditure for screening and primary prevention interventions
associated with the non-LB approach manifest a strategic investment in prevention with
an overall goal of avoiding expensive downstream costs of treating CVD in the false
negative cases. The lower follow-up costs associated with the approach reflects how the
absolute CVD risk scores enable directing intensive interventions to those who need them
most as widely reported in the literature (Beswick et al., 2008; Wan et al., 2009).
In the cost-effectiveness analysis where the LB absolute CVD risk approach was
considered as the status quo, the non-LB absolute CVD risk approach also helped detect
more true CVD cases at a lower cost. The LB absolute CVD risk approach had a 14%
higher average cost-effectiveness ratio. Over the 12year follow-up period, the discounted
costs were 9% greater in the LB absolute CVD risk approach and 6% fewer CVD cases
were identified.

130

The cost of screening using the LB approach was about three times higher per
person compared to the non-LB approach, but the cost of preventive interventions was
comparable for both strategies. The cost of follow-up visits was high in the non-LB
absolute CVD risk approach since more individuals met the treatment threshold
(moderate risk category) when screened using this approach.
The high number of discounted false negatives associated with LB approach (15
more) increased the downstream expenditure of treating the resultant CVD cases. These
downstream expenses make a strong case why the high sensitivity associated with the
non-LB Framingham algorithm makes it superior to the LB approach. Reducing the
number of false negative cases cuts down expensive downstream costs. It is important to
point out that although the false negative cases associated with the LB approach are
higher than the individual CVD risk factors approach, they occur later and are hence
costed using heavily discounted treatment costs.
The higher downstream costs also indicate that the costly screening associated
with the LB approach was not matched with enhanced sensitivity. The slight
improvement in specificity may be helpful in cases where false positive cases could be
subjected to adverse therapies. However, from a cardiovascular standpoint, adverse
effects from preventive therapies for the most part have less impact than unmitigated
CVD risk. The lack of significant improvement in sensitivity/specificity with additional
testing of lipids raises questions about the need for and relevance of these tests in
predicting CVD. It is important to point out that while absolute CVD risk scores are
recommended to guide treatment by major evidence based guidelines, caution is given
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against ignoring individual risk factors (World Health Organization, 2007). For instance,
screening of lipids and other biomarkers could be helpful based on clinician’s discretion,
especially in populations which have a tendency towards subclinical dyslipidemia
without elevations in non-LB indicators such as BMI.
Implementing the non-LB rather than the LB approach would save about $50,000
for every extra true CVD case detected. The negative incremental cost-effectiveness ratio
denotes that the non-LB approach is both more effective, and less costly compared to the
status quo.
Possible relevance to sub-Saharan Africa (SSA)
Although the global burden of disease statistics have been used to support a
premise that SSA is exempt from the epidemic of CVD sweeping across developing
countries, the limitations of the estimates have been detailed in various studies (R. S.
Cooper, Osotimehin, Kaufman, & Forrester, 1998; Kariuki, Stuart-Shor, Leveille, &
Hayman, 2015). The few rigorous studies focusing on CVD risk factors in the region
suggest that the region may not be spared from the epidemiological transition as
previously thought.
Results from the STEPwise approach to Surveillance (STEPS) surveys
commissioned by the WHO indicate that more than 75% of all STEPS participants in
sub-Saharan Africa have had at least one major risk factor for CVD. The most prevalent
risk factors observed across the region include: high age-adjusted BMI especially in
women, elevated systolic blood pressure, low consumption of fruits and vegetables, and
increased levels of fasting blood glucose (Mensah, 2013).
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A Malawian national representative survey conducted in 2009 using the STEPS
approach reported that the age-adjusted prevalence of hypertension was 33.2% in
participants aged between 25 to 64 years. Seventy-five percent of these participants
reported never having their blood pressure checked previously, and over 94.9% of those
with hypertension were not aware of their condition (Msyamboza, Kathyola, Dzowela, &
Bowie, 2012). Similar observations have been made by other researchers in sub-Saharan
Africa who have reported high rates of hypertension, sometimes exceeding those
observed for the same age group in developed countries (Mathenge, Foster, & Kuper,
2010).
These data suggest that the epidemiology of CVD in SSA may not well
understood or appreciated in the current global burden of disease statistics. Ignoring the
problem, as it is currently happening, would lead to missed opportunities for primary
prevention which eventually translates to high downstream costs of treating CVD as
demonstrated in the cost-effectiveness analysis.
The equivalence of regression coefficients and comparability of performance
between the blacks and whites in the US suggests that the validated non-LB Framingham
algorithm may perform well even among groups with varying social determinants of
health. Therefore, despite the well-known differences in social determinants of health, the
validated non-LB Framingham algorithm may provide a beginning point for feasible
CVD prevention in SSA pending validation studies.
The impressive benefits of primary prevention compared to no intervention has
been simulated for SSA. For instance, pharmacotherapeutics primary prevention efforts
targeting populations with more than 25% ten-year absolute risk of CVD were associated
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with an incremental cost-effectiveness ratio of $771 for each healthy year of life saved
(QALY) (Gaziano, Opie, & Weinstein, 2006). Despite the current economic constraints
in SSA, the estimated cost-effectiveness ratios for primary prevention are still considered
feasible because they are below the WHO threshold which considers an intervention to be
cost-effectiveness if it costs less than three times the gross national income per head to
gain a QALY (Murray, Evans, Acharya, & Baltussen, 2000).
Conclusion
Taken in total the results observed in this study demonstrate the validity and costeffectiveness of the non-LB Framingham CVD risk assessment algorithm. The non-LB
approach could provide a valuable and efficient alternative to the traditional LB-based
approaches in the ongoing efforts to address the high burden of CVD in underserved
communities especially the black population in the US. Due to lack of local dataset data
or locally derived algorithms, the validated non-LB Framingham CVD risk assessment
algorithm may provide a beginning point for initiating feasible CVD risk surveillance and
guiding prevention programs in SSA.
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